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CHAPTER I 
INTRODUCTION 
An important characteristic of malignant tumors is their 
ability to invade normal tissue and to proliferate at distant 
sites (metastasis). This ability distinguishes benign and 
malignant tumors. It is the production of metastases which 
makes cancer such a difficult disease to treat and is 
ultimately responsible for the death of the patients. The 
reasons why cancer cells metastasize are currently unknown. 
It is known, however, that not all malignant cells within a 
tumor have the capacity to form distant colonies. Clearly 
therefore, the properties of cancer cells which enable them 
to form metastases are different from those responsible for 
tumorigenesis. 
The major steps in the invasive and metastatic process 
include: detachment of cells from the primary tumor; 
penetration of the extracellular matrix and basement membrane; 
invasion of the vasculature to enter the blood circulation 
(intravasation); arrest in the capillaries at the secondary 
sites (attachment); invasion through the capillary wall 
(extravasation) and finally, colonization and proliferation 
in the distant tissues. 
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Since the extracellular matrix, 
basement membrane and capillary wall consists primarily of 
macromolecules such as collagen, proteoglycans, elastin and 
glycoproteins, it has been proposed that proteolytic enzymes 
may be responsible for their degradation thereby facilitating 
tumor cell invasion and, in turn, metastasis (Jones and De 
Clarck, 1982; Recklies et al, 1982b; Liotta et al, 1983: 
Mullins et al, 1983; Pauli et al, 1983). Consistent with this 
hypothesis, numerous studies have reported increased levels 
of proteolytic enzymes produced by tumor cells. These include 
neutral metallo-proteinases such as collagenase (Liotta et al, 
1982), serine proteinases like tissue plasminogen activator 
(Moacatelli et al, 1980), and several lysosomal proteinases 
including cathepsin B (Sloane et al, 1981; Mort et al, 1981; 
Recklies et al, 1982a and 1982b; Dufek et al, 1984), cathepsin 
L (Gal and Gottesman, 1986; Troen et al, 1988) and cathepsin 
D (Capony et al, 1987; Maudelonde et al, 1988). Among these 
candidate proteinases which may play a role in the invasion 
and metastasis process, cathepsin B has been extensively 
investigated. 
Many studies have reported a positive correlation between 
cathepsin B activity and malignant tumors (Pool et al, 1978; 
Recklies et al, 1980; Sloane et al, 1984a; Koppel et al, 1984; 
Baici and Knopel, 1986; Keppler, 1988; Krepela et al, 1989 and 
1990). Increased secretion of cathepsin B-like enzymes has 
been observed in ascites fluid from patients with· various 
3 
kinds of malignant tumors (Pietras and Roberts, 1981; Mort et 
al, 1981 Dufek et al, 1984) and in conditioned media from 
cultured human and murine mammary carcinoma (Recklies et al, 
1982a; Petrova-Skalkova et al, 1987). The molecular basis for 
the increased levels of cathepsin B activity found in the 
tumors remains unknown. Possible factors include mutation in 
the cathepsin B gene or differences in transcription, 
translation, and post-translational processing of cathepsin 
B. Furthermore, the distribution of cathepsin B is often 
altered in tumor cells, for example, it has been found to be 
association with the plasma membrane (Pietras and Roberts, 
1981; Keren and LeGrue, 1988,) and secreted into the 
extracellular medium. It is not known whether these phenomena 
are results of a cellular defect in post-translational 
processing, or is due to the synthesis in tumor cells of a 
form of cathepsin B which lacks amino acid sequences that 
normally target this enzyme to lysosomes. 
The goal of this study is to use molecular biological 
methods to investigate the expressions and structure(s) of 
cathepsin B gene in normal tissues and in malignant tumors, 
and to investigate the relationship between cathepsin B 
expression and metastatic potential. If cathepsin B or any 
other proteinase could be proven to play a role in the spread 
of human cancers and its mechanism could be understood, 
inhibition of this enzyme could open up new therapeutic 
approaches for the control of malignancy. 
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In this research I have examined the mRNA levels for 
cathepsin B in normal tissues (rat and mouse) and in malignant 
tumors (rat carcinosarcoma and mouse melanoma variants with 
different metastatic potentials) ; compared tumor cathepsin B 
mRNA with normal cathepsin B mRNAs; cloned the three mouse 
cathepsin B mRNA transcripts in mouse melanoma and determined 
their sequences; cloned mouse cathepsin B gene and determined 
its structure, including the transcription start site and 
putative promoter region; and investigated the possible 
mechanisms for differential expressions of cathepsin B gene 
in normal tissues and malignant tumors. 
I also examined mRNA levels for other lysosomal 
cathepsins (D, H, L and S) in normal tissues and malignant 
tumors to determine whether these lysosomal cathepsins are 
over-expressed at the same time or whether only specific 
cathepsin(s) has(have) increased expression in certain tumors. 
CHAPTER II 
REVIEW OF THE RELATED LITERATURE 
THE CELLULAR PROTEASES 
The term proteases have been adopted for proteolytic 
enzymes by the International Union of Biochemistry 
(International, 1979). Proteases include two distinct groups: 
exopeptidases (peptidases) and endopeptidases (proteinases). 
However, some proteases, such as cathepsin B, cathepsin H and 
cathepsin D, have both exo- and endo-peptidase activities, 
for the sake of simplicity those proteases are usually called 
proteinases since their predominant actions are endopeptidase 
activities. 
Exopeptidases are subclassified as carboxypeptidases, 
aminopeptidases, dipeptidylpeptidases, peptidyldipeptidases, 
dipeptidases and omega peptidases. 
The endopeptidases are more commonly called proteinases 
and five classes are recognized for the purpose of 
nomenclature (Barrett, 1980b). The proteinases are unique 
among enzymes in that their classification depends on the 
5 
catalytic mechanism of their active centers. 
6 
These five 
classes are: serine proteinase, cysteine proteinases, aspartic 
proteinases, metallo-proteinases and other proteinases. I 
will briefly review each of the first four classes of the 
proteinases which are all reported to be involved in tumor 
metastasis. Next I will introduce lysosomal cathepsins and 
their correlation with malignant tumors in more detail, 
emphasizing cathepsin B which is main object of my 
dissertation. 
Serine Proteinases 
Serine proteinases include trypsin, chymotrypsin, 
elastase, coagulation factors, leukocyte elastase, cathepsin 
G, chymases, plasminogen activators and so on. They all have 
a serine in their active sites, are active at the neutral pH 
and need no cofactors. Based on extensive homologies have 
been demonstrated for these enzymes it is a reasonable 
hypothesis that they have all diverged from one primitive 
enzyme (Hartley, 1970). Serine proteinases are abundant in 
the body. They are synthesized as inactive precursors that 
require limited proteolysis to activate them. Serine 
proteinases are controlled by cascades of activating enzymes 
and a system of protein proteinase inhibitors. About 10% of 
human plasma proteins consists of Ser-proteinase inhibitors, 
the most abundant being a 1-proteinase inhibitor and a 2-
macroglobulin. Two similarly related Ser-proteinases that 
have been of particular interest in relation to the growth of 
cancer cells are plasmin and plasminogen activator. 
~steine Proteinases 
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The proteinases that depend for activity on an active 
site cysteine residue (cysteine proteinases) are currently the 
subject of very active research. In mammalian system, these 
include lysosomal cysteine proteinases, such as cathepsin B, 
cathepsin H, cathepsin L, cathepsin S and cathepsin N 
(Bareett, 1981), and non-lysosomal cysteine proteinases, such 
as calpains (Murachi et al, 1981). The pH optima for the 
group of lysosomal cysteine proteinases is about pH 6 with 
many substrates and they are unstable above pH 7 (Barrett and 
Kirschke, 1981; Barrett, 1984). The lysosomal cysteine 
proteinases are synthesized as a large precursor which 
undergoes proteolytic maturation. Their mature forms are 
normally confined to the lysosome and play an important 
function in intracellular protein metabolism. In neoplasms, 
some lysosomal cysteine proteinases, such as cathepsin B, are 
found secreted into extracellular environment and their pH 
tolerance seems increased as well (Barrett, 1980a). Calpains 
are ca2• activated, cell membrane associated cysteine 
proteinases (Barth and Elce, 1981; Dayton and Schollmeryer, 
1981) and two forms of calpains have been detected (Dayton et 
al, 1976; Mellgren, 1980). The major distinction between the 
two forms of the enzymes is that they need different 
concentrations of ca2• for their maximal activities. However, 
the two forms have similar Properties: both are active 
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optimally at pH 7.5, both are inhibited by sulphydryl 
modifying reagents and exogenous inhibitors of cysteine 
proteinases and both appear to consist of two subunits. 
calpains have very restricted proteolytic activities and their 
protein substrates include neurofilament proteins, c-protein, 
demin, filamin, vimentin and troponins I and T (John et al, 
1984). 
Aspartic Proteinases 
The aspartic proteinase group has as its major members, 
pepsin, renin, and cathepsin D. The most studied pepsin is 
responsible for the digestion of food proteins in the strongly 
acidic content of the stomach. cathepsin D is a lysosomal 
enzyme and makes an important contribution to intracellular 
proteolysis in the acidic environment of the lysosome. The 
evolution of renin from the hypothetical cathepsin D-like 
archetype has taken a quite different turn. It is stable and 
active at neutral pH and is highly specific for the cleavage 
of the leu-leu bond that generates angiotensin I from 
angiotensinogen. This cleavage follows the releases of renin 
into the blood by kidney in response to low blood pressure. 
Cathepsin D has been found to be regulated by estrogens 
in breast cancer (Henry et al, 1990) and correlated with 
invasive and/or proliferative breast cancer (Rochefort et al, 
1987, Maudelonde, 1988) and endometrial carcinoma (Maudelonde 
et al, 1990). 
Metallo-Proteinases 
9 
Examples of metallo-proteinases include pancreatic 
carboxyl peptidase, thermolysin and collagenases. Collagenase 
is a remarkably specific enzyme: it cleaves all three chains 
of the triple helix of collagen molecule at a single point. 
rt is not known to act on other proteins, except in that it 
seems to cleave the a 2-macroglobulin molecule in becoming bond 
by this inhibitor as part of the mechanism of the inhibition 
of collagenase (Werb et al, 1974) 
The neutral to slightly alkaline pH optimum of the 
metallo-proteinases, together with their sensitivity to 
inhibition by thiols, seem to suit them best for an 
extracellular function. This impression is reinforced by the 
observation that metallo-proteinases are secreted from cells 
and not normally stored within them. There have been studies 
of collagenase in relation to a variety of tumors (Bauer et 
al, 1977; Dabbous et al, 1977; Ohyama and Hashimoto, 1977). 
Figure 1. The Mode of Action of Lysosomal Cathepsins in 
Intracellular Protein Metabolism 
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Intracellular proteins are sequestered in autophagosomes, 
which eventually fuse with lysosomes containing cathepsins 
capable of degrading proteins to amino acids and small 
peptides (Katunuma and Kominami, 1987} 
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CATHEPSIN B AND OTHER LYSOSOMAL CATHEPSINS 
Lysosomal cathepsins consist of two classes of 
proteinases, cysteine proteinases and aspartic proteinase. 
Lysosomal cysteine proteinases are thought to be the most 
active enzymes involved in intracellular protein catabolism 
(Fig. 1) (Katunuma and Kominami, 1983 and 1987). The main 
lysosomal aspartic proteinase is cathepsin D, while the 
lysosomal cysteine proteinases mainly include cathepsin B, 
cathepsin H, cathepsin L and cathepsin S. Among these, 
cathepsin B has been the most thoroughly investigated enzyme. 
Cathepsin B 
Cathepsin B has been isolated from various mammalian 
species and tissues, such as rat 1 i ver, bovine spleen and 
liver (Otto, 1971), and human spleen and liver (Barrett, 
1973). Using the immunochemical method, cathepsin B has been 
located within macrophages (Howie et al, 1985), fibroblasts 
(Mort et al, 1981), neurones (Howie et al, 1985), myocytes 
(Bird et al, 1985) and the epithelial cells (Howie et al, 
1985) of various tissues. Physically important proteins that 
can be degraded by cathepsin B include cartilage proteoglycan, 
collagen, contractile proteins of muscle and skin, hemoglobin, 
immunoglobulin G (Barrett, 1977 and l980a), glucagon (Aronson 
and Barrett, 1978), aldolase (Bond and Barrett, 1980), laminin 
(Lah et al, 1989), elastin (Mason et al, 1986), fibrinogen 
(Gabrijelcic et al, 1988) and fibronectin (Recklies et al, 
1982b). cathepsin B also functions in the acti va-tion of 
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zymogens to enzymes, such as activation of trypsinogen to 
trypsin (Figarella et al, 1988) and procollagenase to 
collagenase (Barrett, 1980a) . In addition, cathepsin B has 
been suggested to have functions in the conversion of some 
hormones and other biologically important proteins from their 
precursors, such as albumin from proalbumin (Taber, 1973), 
renin from prorenin (Takahashi et al, 1982; Taugner et al, 
1985; Shinagawa et al, 1990), thyroid hormones from 
thyroglobulin (Nakagawa et al, 1981a and b), proendorphin to 
endorphin (Suhar and Marks, 1979) and proinsulin to insulin 
(Steiner et al, 1974; Kirschke et al, 1980; Docherty et al, 
1982; Orci, 1985, 1986 and 1987). Moreover, cathepsin Bis 
considered the enzyme which processes distinct epitopes on 
myoglobin (Takahashi et al, 1990). At present, the full 
spectrum of the biological role of cathepsin B is still not 
quite clear but its very broad tissue distribution suggests 
it has important functions. 
The mature form of cathepsin B has a molecular weight of 
26 kd. Its pH optimum is about 6 with many substrates and it 
becomes unstable above pH 7 (Barrett, 1977) • Several 
synthetic substrates are very specific to cathepsin B, such 
as carbobenzyloxy-alanine-L-arginine-4-methoxy-B-naphthylamide 
and carbobenzyloxy-L-arginine-L-arginine-2-naphthylamide. 
The specific activity of cathepsin B on these substrates is 
200 times higher than that of other cathepsins. Flurogenic 
and chromogenic synthetic substrates are the most common 
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substrates used in enzyme assays for determination of the 
cathepsin B activity (Barrett, 1973 and 1986; Bajkowski and 
Frankfater, 1975) 
cathepsin B is structural and functional homologous with 
a plant cysteine proteinase-papain (Bajkowski and Frankfater, 
1983a) and has a similar enzymatic mechanism to papain 
(Bajkowski and Frankfater, 1983b). Cathepsin B from rat, 
porcine, bovine and human have been found to exist in a 
single-chain form and in a two-chain form composed of a light 
and heavy chain. The light and heavy chain most likely result 
from limited proteolyses in the N-terminal part of the enzyme 
and are presumed to be connected via a disulfide bridge 
(Takahashi et al, 1984; San Segundo et al, 1985; Chan et al, 
1986). The amino acid sequences of rat (Takio et al, 1983) 
and human (Ritonja et al, 1985) cathepsin B have been 
determined. The homology between mammalian cathepsin B 
sequences with the sequence of papain provides evidence that 
lysosomal and plant cysteine proteinase have evolved from a 
common ancestor and cathepsin B is a highly conserved enzyme 
through evolution. 
Biosynthetic studies have indicted that cathepsin B is 
derived from a larger precursor form, procathepsin B, which 
in its glycosylated state has a molecular mass of about 40 kd 
(Steiner et al, 1984a and 1984b; Nishimura and Kato, 1987). 
Procathepsin B is an inactive form which can be activated in 
vitro upon limited cleavage by the enzyme pepsin. The 
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procathepsin B is derived from preprocathepsin B which is 
synthesized on the rough endoplasmic reticulum. 
Preprocathepsin B is converted to procathepsin B by a signal 
peptidase during the process of transportation into the lumen 
of the rough endoplasmic reticulum. The procathepsin B is 
transported to the lysosome where it is slowly converted to 
mature cathepsin B. Procathepsin B may also appear in other 
compartments such as the secretory granule in insulinomas 
(Docherty et al, 1984) and secrete into the culture media 
(Pietras et al, 1981; Recklies et al, 1982a: Archkar et al, 
1990) • 
The preprocathepsin B cDNAs in human (Chan et al, 1986, 
Fong et al, 1986), rat (Segundo et al, 1986) and mouse (Chan 
et al, 1986) have been cloned and sequenced. The predicted 
primary structure of each of them has 339 amino acids, 
including a 17-residue predominantly hydrophobic sequence at 
N-terminus, 62-residue N-terminal propeptide extension 
connected to the 254-residue mature single chain cathepsin B, 
and a 6-residue carboxyl-terminal extension. The rat and 
mouse cathepsin B amino acid sequences are strongly 
homologous, with 90% identity. The human and rat (or mouse) 
amino sequences are 84% homologous in mature proteins and 
about 50% homologous in the prepro-regions and c-terminal 
peptides. Human cathepsin B gene is located in chromosome 
8p22 (Tsui et al, 1989). 
Cathepsin L 
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Cathepsin L is also a glycoprotein with a molecular 
weight of 27,000-30,000 and consists of two chains linked by 
disulfide bonds, subunit Mr values 22,000-25,000 and 5,000-
7,000. The pH optimum is 6.0 for the hydrolysis of 
methylcoumarylamide substrates, but is 3. 5 for the degradation 
of glomerular basement membrane. Cathepsin L is completely 
inactivated by the active site directed inhibitor, Z-Phe-Phe-
CHN2 (0.56 µM) under a condition where cathepsin B is 
unaffected. Cathepsin L shows greater activity against 
protein substrates than other lysosomal cysteine proteinases, 
for example, it is significantly more active in degrading 
glomerular basement membrane than cathepsin B, elastase, 
trypsin or bacterial collagenase (Baricos et al, 1988), is at 
least an order of magnitude faster than cathepsin B in 
degrading collagen (Mason et al, 1986), and is 100-fold more 
active than cathepsin B in hydrolysis of a tritiated elastin 
(Mason et al, 1986). Pro-cathepsin L has an molecular weight 
of 39,000-42,000 (Smith and Simpson, 1989). The 
preprocathepsin L cDNAs of mouse (Portnoy et al, 1986, Joseph 
et al, 1988), rat (Ishidoh et al, 1987b) and human (Mason et 
al, 1986, Joseph et al, 1988) has been cloned and sequenced. 
Based on predicted amino acid sequences both rodent and human 
enzymes show similar organization. However, the length of 
rodent cathepsin L is 335 amino acids while that of human 
cathepsin L is 334 amino acids. Each begins with a 17 amino 
acid long hydrophobic sequence that ends in Ala-X-Ala, a 
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proposed consensus cleavage site for signal peptides (Perlman 
and Halvorson, 1983), followed by a 96 amino acid propeptide. 
The rodent enzyme displays one more carboxyl terminal amino 
acid than does the human enzyme. It is not known if this 
residue is present in the mature protein or is removed during 
proteolytic processing. The gene of rat cathepsin L has also 
been cloned (Ishidoh et al, 1989b). The gene consists of 8 
exons and 7 introns spanning 8. 5 kilobase pairs. Human 
cathepsin L gene is located in chromosome 9q21-q22 (Smith and 
Simpson, 1989). 
cathepsin H 
Cathepsin H was first isolated from rat liver (Kirschke 
et al, 1976 and 1979) and subsequently from human liver 
(Schwartz and Barrett, 1980). It exists as a single chain 
form with a molecular mass of about 28,000 Dalton and a two-
chain form with molecular masses of 22,000 and 6,000 Dalton. 
It differs from cathepsin B and L in being active both on 
amino terminal blocked and unblocked synthetic substrates. 
cathepsin H has not only endopeptidase activity but also 
aminopeptidase activity (Kirschke et al, 1976). It has an 
optimum pH value of 6.5 for most of substrates. Its 
sensitivity to chemical inhibitors is generally similar to 
that of cysteine proteinases, but it is unaffected by 1 
leupeptin, a concentration which gives complete inhibition of 
cathepsins B and L. As proteins, cathepsin B and H are easily 
separated by DEAE-cellulose or concanavalin A-Sepharose while 
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cathepsin Lhasa much higher affinity for CM (carboxymethyl)-
cellulose at pH 5.0 than the other two enzymes (Schwartz and 
Barrett, 1980). Little is known about the proteins which 
cathepsin H can hydrolyze. Kirschke et al (1980) have shown 
that neither rat nor human cathepsin H has detectable 
collagenolytic activity. As with the other cysteine 
proteinases cathepsin H is synthesized as a larger precursor 
which is posttranslationally processed. This is confirmed by 
both amino acid sequencing and cDNA cloning. The ·rat 
cathepsin H amino acid sequence was determined by Takio et al 
(1983). Rat preprocathepsin H cDNA (Ishidoh et al, 1987a, 
Qian et al, 1990) and human cathepsin H cDNA (Fuchs et al, 
1988) have been cloned and sequenced later. The deduced amino 
acid sequences from the nucleotide sequences indicate both rat 
and human preprocathepsin cathepsin H have 248 amino acids 
including 21 residues of a signal peptide, 92 residues of 
propeptide and 220 residues of mature protein. Cathepsin H 
does not have carboxyl terminal peptide extension as does 
cathepsin B. The two sequences are highly homologous with 86% 
identity. Interestingly, the propeptides from the two species 
are 100% identical. Rat cathepsin H gene has been cloned 
recently (Ishidoh et al, 1989a). It consists of at least 12 
exon spanning in total more than 17 . 5 kb. The human 
cathepsin H gene is located in chromosome 15q24-q25 (Cox and 
Donlon, 1989). 
Cathepsin s 
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cathepsin S was originally purified from bovine lymph 
nodes (Turnsek et al, 1975) and bovine spleen (Locnikar et al, 
1981; Kirschke et al, 1986) and then rabbit spleen (Maciewicz 
and Etherngton, 1988) . Cathepsin S has been detected in 
bovine kidney, spleen, lung and lymph nodes by immunochemical 
methods but not in liver, heart muscle, skeletal muscle, 
intestine or stomach by the same method (Kirschke et al, 
1989). Cathepsin s appears as a single protein with molecular 
weight about 24, 000 under reducing and non-reducing conditions 
(Locnikar et al, 1981; Kirschke et al, 1986). It has been 
shown that this enzyme has some similarity to cathepsin L, but 
is clearly different protein as judged by differences in the 
hydrolysis of Z-Phe-Arg-NHMec as well as in inhibition by z-
Phe-Phe-CHN2 (Kirschke et al, 1984 and 1986). Cathepsin s has 
been found to be able to hydrolyze hemoglobin, albumin, and 
azo-casein at a similar rate to cathepsin L below pH 7. O. 
Cathepsin s can also degrade insoluble collagen though at a 
lower rate to cathepsin L (36%). One property of cathepsin 
s by which this enzyme differs from all other lysosomal 
proteinases has to be emphasized: this is the stability of the 
active enzyme at neutral pH values. Although it has an 
optimum pH below 7 for most tested proteins, cathepsin S 
remains stable and degrades proteins at pH 7.5 where cathepsin 
Lis inactive (Kirschke et al, 1989). Mouse cathepsin s cDNA 
has been cloned and sequenced (Chan et al, unpublished data). 
The sequencing information indicates cathepsin S is also 
synthesized as a larger precursor. 
~athepsin D 
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Cathepsin D is a unique aspartic proteinase known to be 
lysosomal rather than secretory. Unlike cysteine proteinases 
which have a Cys in their active sites, cathepsin D has two 
Asp in the active site which are involved in the mechanism of 
catalysis. The main physiological role of cathepsin D is the 
break down of tissue proteins. This function makes cathepsin 
D different from most other aspartic proteases. Like the 
cysteine cathepsins, cathepsin D is a glycoprotein, has an 
acid pH optimum and loses activity at or above pH 7. However, 
its molecular mass (approximately 42 kilodaltons) is much 
larger than that of cysteine cathepsins. Cathepsin D is not 
only a endopeptidase but is also a carboxypeptidase. It has 
been identified and purified from a wide variety of tissues. 
Cathepsin D is mainly a two-chain protein, although a small 
fraction of the single-chain species is always present 
(Shewale et al, 1985). Cathepsin Dis thought to make an 
important contribution to intracellular proteolysis in the 
acidic environment of the lysosomal interior. The powerful 
Asp-proteinase inhibitor-pepstatin (Knight and Barrett, 1976) 
has been show to cause some slowing of protein break down in 
perfused liver when carried into the cells in liposomes (Dean, 
1976). In normal endometrium cathepsin D is regulated by 
progesterone. Cathepsin D could be viewed as an indicator of 
endometrial transformation, suggesting that cathepsin D might 
20 
have a role in the biological and morphological modification 
that occur during the luteal phase. It may play a role in the 
cyclic destructive autophagy and remodeling of endometrium in 
the absence of nidation (Maudelonde et al, 1990). Human 
cathepsin D cDNA has been cloned and sequenced (Faust et al, 
1985). Sequencing data reveals that mature cathepsin D is 
derived from procathepsin D which has a molecular mass of 52 
kD while Procathepsin D is in turn derived from 
preprocathepsin D during its transport into the lumen of ER. 
The human cathepsin D gene is located in chromosome llpl5.5 
(Junien and McBride, 1989). 
Summaries of properties and characteristics of lysosomal 
cathepsins are listed in Table 1 and 2, respectively. 
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Table 1. Comparison of Properties of Lysosomal cathepsins 
Cathepsin B Cathepsin H Cathepsin L Cathepsin s Cathepsin D 
Molecular ~eight 29000 26000 30000 25000 42000 
(daltons) 
pl 4.9·5.3 6.5-7.5 5.8-6.l 6.3-6.9 3.2-3.5 
Optimum pH 6.2 6.5 5.5 6.5 5.6 
Catalytic Type Dipeptidyl Amino· Carboxy· 
carboxy- peptidase peptidase 
peptidase activity activity 
activity 
Moderate Variable Very High Very High High 
endoprotease endoprot::ease endoprotease endoprotease endoprotease 
act::ivity activity activity activity activity 
Suitable Synthetic Z·Arg-Arg· Arg·NMec Z·Phe·Arg· Bz-Phe·Val Lys-Pro-Ala· 
Substrate NMec NMec Arg-NHMec Glu·Phe· 
(N02)Phe-Leu 
Leupeptin High Low High No 
Inhibition 
Pepstain 
Inhibition No No No No High 
Z·Phe·Phe-CHN Low Low High Low No 
Inhibition 
E-64 Inhibition High Low High No 
Leu·CH3Cl Inhibition Low High Low t\o 
Monnose 6-
Phosphate Marker Yes Yes Yes Yes Yes 
Glycoprotein Yes Yes Yes Yes Yes 
Single-Chain Form Yes Yes Yes Yes Yes 
Two-Chain Form Yes Yes Yes No Yes 
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Table 2. Characteristics of Lysosomal Cathepsins 
B H L s D 
Preproprotein (aa) 339 335 334 (human) 342 412 
335 (rat) 
Pre-Peptide (aa) 17 21 17 26 20 
Pro-Peptide (aa) 62 93 95 100 44 
Mature Protein (aa) 254 220 221 (human) 216 348 
222 (rat) 
Potential Glycosylation 
Sites (pro+mature) l+l 2+1 0+2 l+O 0+2 
Cysteines (pro+mature) 1+14 1+8 0+11 1+10 0+7 
Chromosome loci Ch1.111an) 8 15 9 ? 11 
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coRELATION BETWEEN CATHEPSIN ACTIVITY AND MALIGNANT TUMORS 
A large body of evidence has accumulated implicating 
proteolytic enzymes as playing a key role in the process of 
invasion and metastases of tumors (Strauli et al, 1980; 
Goldfarb and Liotta, 1986). As mentioned above, among these 
proteinases, most attention has been focused on the serine 
proteinase plasminogen activator (Wang et al, 1980; Carlsen 
et al, 1984), Plasmin (Liotta et al, 1981), the cysteine 
proteinases cathepsin B (Recklies et al, 1980; Krepela et al, 
1990), and L (Vasishta et al 1985; Sheahan et al, 1989), the 
aspartic proteinase cathepsin D (Rochefort et al, 1987; 
Maudelonde et al, 1990) and the metallo-proteinase collagenase 
type IV (Bauer et al, 1977; Ohyama and Hashimoto, 1977; 
Turpeenniemi-Hujanen et al, 1985). 
Increased cathepsin B activity has been found in a 
various metastatic tumors by using enzyme assays. For 
instance, it is elevated in serum of women with genital tract 
cancers, especially those patients with invasive carcinoma 
(Pietras et al, 1979), in human malignant breast tumors (Pool 
et al, 1978, Recklies et al, 1980), in a rabbit V2 carcinoma 
cells (Baici and Knopfel, 1986), in rat metastatic pancreatic 
cancer variant (Koppel et al, 1984), in marine Bl6 melanoma 
(Sloane et al, 1982) and Lewis lung carcinoma (Sloane et al, 
1984b) with high metastatic potential, in a rat sarcoma LW13K2 
which produces spontaneous metastases (Krepela et al, 1989), 
in human primary liver cancer (Dufek et al, 1984),· colonic 
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cancer (Keppler et al, 1988a) and human lung tumors (Krepela, 
et al, 1990). 
cell culture experiments indicate that cathepsin B may 
have a cellular detachment function similar to that seen in 
trypsin in detachment of cells from glass surfaces (Sylven et 
al, 1968). Considering the known ability of cathepsin B to 
degrade proteoglycans (Morrison et al, 1973), collagen 
(Burleigh et al, 1984), fibronectin (Recklies et al, 1982b), 
laminin (Lah et al, 1989), and to activate trypsinogen to 
trypsin and procollagenase to collagenase (Barrett, 1980a), 
the elevated cathepsin B activity in tumor cells suggests it 
could play a role in degradation of the extracellular matrix 
and the release of tumor cells. Further studies have shown 
that increased cathepsin B activity can be found in 
association with the plasma membrane. Thus, cathepsin B may 
act at sites of local degradation where the tumor cell 
membrane and the extracellular matrix come into direct 
contact. For example, cathepsin B activity has been found in 
the plasma membrane fractions from the spontaneous BDX rat 
anaplastic sarcoma (Koppel et al, 1984), from human pancreatic 
adenocarcinoma cells (Zucker et al, 1985~ Zucker, 1988), from 
mouse melanomas in amounts which correlated with metastatic 
potential (Sloane et al, 1986), from squamous carcinoma cells 
of the human ectocervix but not from non-neoplastic cervical 
cells (Pietras and Roberts, 1981), and in association with 
the insulin secreting granule of a transplantable rat 
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insulinoma (Docherty et al, 1984). 
Enzymes possessing cathepsin B-like activity have 
received particular attention because of their extracellular 
release by tumors (Pietras and Roberts, 1981; Bajkowski et al, 
1984). Enzymologically the secreted enzymes are very similar 
to lysosomal cathepsin B in terms of their reactivity to 
synthetic substrates and to inhibitors. They differ from the 
lysosomal cathepsin B, however, in that they have higher 
molecular weights, different isoelectric points compared with 
lysosomal cathepsin B and, unlike lysosomal cathepsin B, they 
are active at pH 7. Two major extracellular high-Mr forms 
(both have molecular weights around 40 kd) of human cathepsin 
B have been described, one is latent, another is active. A 
latent form of cathepsin B has been found in ascitic fluid and 
in culture medium of ascites cells from cancer patients. The 
latent enzyme could be rendered active by prior proteinase 
treatment (Mort et al, l98la). In addition, human malignant 
breast tumors in organ culture release a high-Mr form of 
cathepsin B that was detected by its ability to hydrolyze 
synthetic substrates for which lysosomal cathepsin B has high 
affinity (Mort et al, 1980). A similar activity has been 
characterized in culture media of spontaneous mammary tumors 
(Recklies et al, 1982a) and lactating mouse mammary gland 
(Recklies and Mort, 1985a). The active high-Mr cathepsin B 
cleaves a range of synthetic substrate in a similar manner to 
that of the lysosomal enzyme (Mort and Recklies, 1986). The 
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t~o forms of high-Mr cathepsin B (active and latent) proteins 
bave also been detected in murine Bl6a melanoma (Bajkowski et 
1 1984; Qian et al, 1989). a , 
Bellelli et al (1990) have found that parenteral 
administration of papain in mice induced antipapain antibody 
cross-reacting with cathepsin B and cathepsin H. In such 
papain-immunized animals the invasion of the abdominal wall 
tissue (in intraperitoneally transplanted mice) was clearly 
reduced; tumor growth rates were significantly lowered; fewer 
pulmonary metastases were found, and the mean survival time 
increased up to 180%, as compared to the controls. The thiol 
proteinase inhibitor leupeptin has also been reported to 
inhibit metastasis in some experimental system (McCarty, 
1982). 
From the evidence presented above, cathepsin B is a 
strong candidate for involvement in some steps of the 
metastatic cascade. However, it is not clear whether the 
increased cathepsin B activity is a result of an increased 
synthesis of cathepsin B or a result of a decreased 
degradation of the enzyme, whether the secreted tumor-
associated cathepsin B-like enzymes are high molecular weight 
precursor forms of cathepsin B, a mutated cathepsin B or a 
related enzyme from a different gene locus. One study has 
reported that amino acid composition data and peptide mapping 
revealed significant differences between the cathepsin B from 
normal mouse liver and a cathepsin B-like enzyme ·from an 
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analogous tumor (Olstein and Liender, 1983). 
Also, it should be noted that a lack of correlation 
between cathepsin B and metastatic tumors has been reported 
in a rat prostatic adenocarcinomas (Lowe and Issacs, 1984), 
and in the variants of a methychloranthrene-induced sarcoma 
(Mclaughlin et al, 1983). Krepela et al (1989) have proposed 
an explanation for the lack of correlation between cathepsin 
B and metastatic potential of two rat sarcoma variants. They 
found that the variant with high metastatic potential has 
lower intracellular level of cathepsin B activity compared to 
the variant with low metastatic potential. However, in the 
serum-free medium at pH 6.5 the variant with high metastatic 
potential released a significantly higher amount of cathepsin 
B activity into the medium than the one with low metastatic 
potential. They thus suggested that the two variant cell 
lines may have different capabilities to regulate their 
intracellular pH, which could affect the externalization of 
intracellular vesicles containing cathepsin B. In addition, 
they proposed that the mildly acidic microenvironment 
generated and frequently maintained at the surf ace of tumor 
cells could not only trigger cathepsin B release but also be 
favorable for maintaining the activity and the stability of 
the released enzyme. 
Cathepsin L has attracted great attention since a major 
excreted protein (MEP) was cloned from transformed NIH3T3 
cells and it was shown to be cathepsin L (Troen et al 1987; 
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Joseph et al, 1987 and 1988). MEP has long been observed to 
be secreted by transformed murine fibroblasts in cell culture. 
After transformation of murine NIH or BALB 3T3 fibroblasts 
with K-ras, cellular MEP rose from less than 0.02 to 1% of the 
total intracellular protein. The MEP was described as a 
mannose 6-phosphate-containing glycoprotein of Mr 39,000 which 
binds to purified phosphomannosylyl receptor responsible for 
targeting protein to lysosomes. The MEP accounts for up to 
30% of the excreted proteins in transformed fibroblasts. 
similar results apply to transformation by Ha-ras, MSV, SV40, 
and methylcholanthrene (Gottesman, 1978; Gottesman and Sobel, 
1980; Gal et al, 1985; Gal and Gottesman, 1986). Secretion 
of MEP from NIH3T3 cells was also observed upon treatment of 
cells with a tumor promoter, TPA and PDGF (Gottesman and 
Sobel, 1980; Docherty et al, 1985; Frick et al, 1985; Rabin 
et al, 1986). Stimulation of non-transformed 3T3 fibroblasts 
by plating in serum at low density did not significantly 
elevate the basal level of MEP secretion. oenhardt and 
coworkers (1986) examined MEP mRNA expression at different 
points in the cell-cycle (stimulated by serum) and found less 
than a two fold change. The definitive identification of this 
protein as murine cathepsin L was established by isolation and 
sequencing of the corresponding clone from a human kidney cDNA 
library (Mason et al, 1986). Increased cathepsin L activity 
has been found in only a limited number of malignant tumors. 
Human gastric cancer was found to have increased cathepsin L 
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activity by two groups (Vasishta et al, 1985; Watanabe et al, 
1999). So was human breast tumor {Abecassis et al, 1984). 
Sheahan et al {1989) examined 29 colorectal cancer patients 
with z-Phe-Arg-NHMec as substrates and concluded cathepsin L-
like specific activities were significantly elevated {p< 
o.005) in early stage (Dukes'A) (Dukes, 1932) of colorectal 
carcinoma while, in medium and late stages (Dukes'B, c and D), 
it became as low as in normal tissues. Unfortunately Z-Phe-
Arg-NHMec is not specific for cathepsin L since it is also 
hydrolyzed by cathepsin B. Durdey et al (1985) have obtained 
similar results. However, another group (Keppler et al, 
1988a) found the levels of cathepsin L was very low in both 
extracts of colorectal tumors and normal colonic mucosa and 
no MEP was detected in the human colon adenocarcinomas 
checked. Unforturnately, this paper did not identify the 
stages of the tumors. Gottesman et al have hypothesized that 
cathepsin L plays a role in malignant transformation; however, 
up-regulation of the expression of cathepsin L in murine NIH 
3T3 fibroblast was not sufficient to induce a transformed 
phenotype as measured by anchorage or serum independent growth 
or tumorigenesis in nude mice (Kane et al, 1988). Denhardt 
et al (1987) have suggested that cathepsin L plays a role in 
the proteolytic steps of the metastatic cascade since elevated 
mRNA for cathepsin L in ras transf ected fibroblasts correlated 
with the metastatic capability of the transfected cells. 
However, not appreciated at that time is the fact that ras 
30 
transfection of fibroblasts can also increase cathepsin B 
expression and procathepsin B secretion. A role for cathepsin 
L in metastasis would appear a reasonable hypothesis as this 
cysteine proteinase shows the most potent collagenolytic and 
elastinolytic activity in vitro of any of the cathepsins 
(Mason et al, 1986, Kirachke et al, 1982) and it can readily 
degrade intact basement membranes (Baricos et al, 1988). 
Furthermore, cathepsin L activity has been detected on cell 
surface of cultured human colon carcinoma cells (Maciewicz et 
al, 1989) and murine B16 melanoma cells (Rozhin et al, 1989). 
Its presence in plasma membrane may lead to the establishment 
of a local microenvironment in which local degradation of 
basement membrane could happen. The secreted high molecular 
weight cathepsin L by malignant tumor was found to be more 
stable in neutral pH than lysosomal cathepsin L and active as 
a precursor of cathepsin L (Mason et al, 1987; Nishimura et 
al, 1988). Maciewicz et al (1989) have found not only mature 
cathepsin L, but also procathepsin L in culture medium for 
malignant cells is active against an isolated basement 
membrane matrix in vitro. Taken together, the stable latent 
activity of procathepsin L secreted by transformed or 
malignant tumor cells, the evidence for autoprocessing of 
procathepsin L to mature cathepsin L in medium, and the 
significant activity of mature cathepsin L at neutral pH 
argues for a role of cathepsin L in tumor invasiveness or 
metastasis. However, normal rat mammary glands in culture 
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have also been shown to secrete a high molecular weight form 
of cathepsin L (Recklies and Mort, 1985b). 
cathepsin D, although it is a lysosomal proteinase with 
a wide tissue distribution, has been shown to be 
transcriptionally regulated by estrogens in MCF7 cells-a human 
breast cancer cell line (Westley and May, 1987; Cavailles et 
al, 1988). It is secreted as a proenzyme which was first 
described as a 52,000 mol wt protein (Weatley et al, 1980; 
capony et al, 1987) before its identification as cathepsin D 
by molecular cloning and sequencing (Augereau et al, 1988). 
It was found to be mitogenic in vitro (Vignon et al, 1986), 
to stimulate DNA synthesis and mitosis in the rat liver 
(Terayama et al, 1985) and capable of degrading the 
extracellular matrix (Briozzo et al, 1988) , suggesting a 
potential role in mammary carcinogenesis and metastasis 
(Rochefort et al, 1987). 
The 52,000 protein was detected in several human primary 
breast cancers but not in normal breast and endometrium of 
uterus (Garcia et al, 1984). It is fully active in acidic 
molecular organelles (endosomes, lysosomes) without much 
change in its molecular mass, since the autoacti vat ion in 
acidic pH caused only a slight decrease in mass to 51-kD. 
Inhibition of the proteolytic activity by pepstatin suggested 
that the 52-kD protein is an aspartic proteinase. It 
displayed a maximal activity at pH 5.5 and retained some 
activity above pH 6, suggesting that this secreted protease 
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maY act extracellularly in vivo (Capony et al, 1987). The 
cathepsin D level is not significantly regulated in normal 
mammary epithelial cells. The regulation of cathepsin D by 
estrogen might be the result of the increase in the estrogen 
receptor level in the breast cancer cells. This speculation 
was supported by other findings that Cathepsin D mRNA was not 
regulated in an estrogen receptor negative breast tumor cell 
line, BT20, and in two other malignant cell lines Hela and 
A431 (Weatley et al, 1987). 
Some clinical studies using immunoenzymatic technique 
suggested cathepsin D expression in breast cancers is 
associated with prognostic disadvantage. such as Maudelonde 
et al (1988) reported that high levels of cathepsin D 
expression in primary breast cancers are associated with an 
increased propensity for lymph node metastasis based on a 
study of 182 breast cancer cytosol. Similarly, Thorpe et al 
(1989) found that high concentrations of cathepsin D predict 
poor prognosis in primary breast cancer. The agreement 
between prospective (Maudelonde et al, 1988) and retrospective 
studies (Thorpe et al, 1989) of breast cancer patients 
suggests that cytosolic cathepsin D concentrations may have 
a prognostic value independent of other prognostic parameters. 
However, a study of expression of cathepsin D in 94 breast 
cancers by immunohistochemical technique reported conflicting 
result, which suggested that cathepsin D was associated with 
a significant prognostic advantage (Henry et al, 1990). The 
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study found that cathepsin D positive staining was associated 
with presence of estrogen receptors. In the estrogen receptor 
positive breast tumors, cathepsin D staining positive patients 
had significantly prolonged survival. In a very recently 
study, it has been claimed that cathepsin D is a good 
predictor of metastatic breast tumor especially in nude 
negative patients and in women with aneuploid mammary tumors 
(Tandon et al, 1990). 
The regulation of cathepsin D in human normal endometrium 
is mostly due to progesterone, 
cathepsin D level appears to 
not to estradiol, and the 
be higher (3-fold) in 
adenocarcinoma cells than in normal cells . In addition, 
there is a significant correlation between myometrial invasion 
and cathepsin D concentrations. The low level of cathepsin 
D in endometrial cancer appears to be correlated with low 
myometrial invasion (Maudelonde et al, 1990). Since 
myometrial invasiveness is considered to be the major 
prognostic parameter of endometrial carcinoma (Hendrickson et 
al, 1982), the cellular concentration of cathepsin D may be 
of interest as an associated biochemical marker of invasion. 
Another broad set of explanations for increased secretion 
of cathepsins including B, L and D in various of tumors 
involves alterations in protein sorting. Glycosylation 
abnormalities, which have been extensively described for the 
cell surface in malignancy (Dennis et al, 1987), could alter 
sorting of cathepsins, resulting in increased secretion and 
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altered intracellular distribution. An altered transferase 
in I cell disease prevents expression of the mannose-6 
phosphate marker and results in massive secretion of many 
lysosomal constituents (Kornfeld, 1986). Some cells, such as 
J774. 2, appear to lack a properly functioning mannose 6 
phosphate receptor (215 kD receptor), again resulting marked 
secretion of multiple lysosomal species (Gabel et al, 1983). 
Very few correlation have been observed between 
malignant tumors and the other two lysosomal cathepsins, H and 
s. one paper reported that increased cathepsin H activity has 
been found in human brain neoplasms (Chernaia and Reva, 1989). 
Table 3 listed the types of tumors which have been 
reported to have elevated cathepsin activities or secretions. 
Table 3. Enhanced Activities or Secretions of Cathepsins 
in Different Tumors 
Cathepsin B t Liver Cancer 
Mammary Carcinoma 
Melanoma 
Ovarian Carcinoma 
Fibrosarcoma 
Gastric Cancer 
Lung Canc:er 
Cathepsin D t Breast Carcinoma 
Hepatomas 
Gastric Cancer 
Cathepsin L t 3T3 Transformed Cells 
Cathepsin H t Brain Tumor 
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Chapter III 
MATERIALS AND METHODS 
Materials 
Enzymes and chemicals were purchased from Bethesda 
Research Laboratories (Gaithersburg, MD), New England Biolab 
(Beverly, MA) and Boehringer Mannheim Biochemicals 
(Indianapolis, IN). Nitrocellulose filters were from 
Schleicher and Schnell (Keene, NH). a-32P-dCTP (specific 
activity 3,000 Ci/mmol), r-32P-dATP (specific activity 5,000 
ci/mmol) and nick translation kit were from Amersham 
(Arlington Heights, IL). Protected nucleotide monomers and 
reagents for DNA synthesis were from Applied Biosystems 
(Foster City, CA). Mouse cathepsin B (1,200 bp) (Chan et al, 
1986) and rat cathepsin S cDNAs (940 bp) (Chan et al, 
Unpublished data), and rat cathepsin H cDNA (1,400 bp) from 
rat were prepared in our laboratories. A human cathepsin D 
cDNA (2,300 bp) (Faust et al, 1985) was a gift from Dr. J. 
Chirgwin (University of Texas, Health Science Center, San 
Antonio, TX 78284) and mouse cathepsin L cDNA (850 bp) was a 
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gift from Dr. V. Sukhatme (Howard Hughes Medical Institute, 
the University of Chicago, Chicago, IL 60637). Sprague-Dawley 
rats of both sexes were from Dutchland (Denver, PA). Walker-
256 carcinosarcoma, cell line LLC-WRC was obtained from the 
American Type culture Collection (Rockvile, MD). 
The mice used in these studies (C57BL/6, male, 5-7 weeks 
old) were purchased from Jackson Laboratories (Bar Harbor, 
ME). All animals were housed under identical conditions of 
photoperiod, feeding regime and temperature for 1 week in the 
Loyola Animal Facility prior to use. The murine melanoma 
variants B16-Fl, F16-F10, and B16a were obtained from the 
Division of Cancer Treatment Tumor Depository (National cancer 
Institute-Frederick Cancer Research Facility, Frederick, MD) 
(Filder, 1973). The melanomas were propagated in vivo by 
subcutaneous injection of the minced tumor into the right 
axillary region of the host mice. 
Cell Culture 
Freshly dispersed tumor cells were adapted for growth in 
Eagle's Minimum Essential Medium (MEM) containing Hank's salts 
and supplemented with sodium pyruvate, MEM non-essential amino 
acids, 75 units/ml penicillin, 75 µg/ml streptomycin, 25 mM 
HEPES and 10% FBS. Semi-confluent cells were subcultured by 
scraping into 10 ml of incomplete media (MEM), pelleted at 500 
x g and resuspended in fresh medium containing 10% FBS. The 
cells were subcultured approximately once a week for a maximum 
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three times and the media was changed thrice weekly. 
secondary cultures were used during log phase of growth and 
were 70-80% confluent. In a T-75 flask this corresponded to 
approximately 3 x 106 cells with Bl6-Fl, 6 x 106 cells with 
B16-FlO, and 8 x 106 cells with B16a. 
screening of A Rat Liver cDNA Library and DNA Seguencing 
A rat liver cDNA library constructed in A.gtll was a gift 
from Dr. James Hardwick (Argonne National Laboratory) and was 
screened with the synthetic 39 bp-longmixed oligonucleotides. 
The DNA oligonucleotides were synthesized using the 
phosphoramidite methodology (Beaucage and Caruthers, 1981) on 
an Applied Biosystems Model 380A synthesizer and were purified 
by polyacrylamide gel electrophoresis in 7 M urea (Agarwal et 
al, 1981). After plating the library on£. coli LE392, a 
total of 106 plaques were screened. Filters were 
prehybridized (2 hrs) and hybridized (16 hrs) in a solution 
containing 2.5 x Dehhardt's solution/5 x NaCl/Cit/20 mM sodium 
phosphate, pH 6.5/0.1% NaDodS04/20% formamide/50 µg of 
sonicated denatured salmon sperm DNA per ml at 37°C. 
Approximately 5 x 105 of radioactive DNA probe per ml was used 
during hybridization. Hybridized filters were washed at a 
final temperature of 50°C in a final solution of 2 x 
NaCl/Ci/0.1% NaDodS04 • The filters were autoradiographed at 
-10°c with Kodak XAR-5 film and DuPont intensifying screens. 
The positive clones were purified and subcloned into PGEM4Z 
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Ml3 mpl8, mpl9. Sequencing analysis was done using both 
Maxam-Gilbert chemical method (Maxam and Gilbert, 1977 and 
l980) and the dideoxy chain termination method (Sanger et al, 
1977) . 
Total RNA and Poly{A)+ Isolation 
Perfused normal tissues, perfused solid tumors and 
cultured cells (approximately 5-7 x 107 cells), frozen in 
liquid nitrogen and stored at -80°C, were homogenized in 10 
volumes of a solution of 5 M guanidinium thiocyanate, 10 mM 
EDTA, 50 mM Tris-HCl, PH7.5, 14% (v/v) ercaptoethanol. 
Homogenates were centrifuged at 1,000 x g at 4°C for 15 min. 
in a swinging bucket rotor. The RNA was isolated by 
centrifugation through a 5.7 M CsCl, 0.1 M EDTA, PH 7.0 
cushion at 35,000 rpm at 20°C for 16 h in a SW40 swing bucket 
rotor. The RNA was then dissolved in O. 2% SOS, extracted with 
phenol/chloroform and precipitated with ethanol (Chirgwin et 
al, 1979). The integrity of the RNA was examined by agarose 
gel electrophoresis after denaturation with glyoxal and 
dimethylsulfoxide (Maniatis et al, 1982). Poly(A)+ RNA was 
then isolated by oligo ( dT) -cellulose, chromatography (Maniatis 
et al, 1982) • 
Specificity and Sensitivity of the cDNA Probes 
Since the cysteine cathepsins are structurally related 
enzymes with significant homology in primary sequences it is 
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important to establish that each individual cDNA probe 
hybridizes only to the corresponding cathepsin mRNA. To test 
this, a preliminary experiment was performed in which five 
identical dot blots were prepared, 1 ng of cathepsin B, D, L 
and s cDNAs were spotted onto each blot filter. The identical 
blots were hybridized with each of five 32P-labeled cathepsin 
cDNA probes, respectively, and washed under high stringency 
condition as described above. The results indicated each 
probe only hybridized with its corresponding cDNA. No cross 
reactivity was observed under the condition employed. To test 
the sensitivity of the cDNA probe, five dot blots were 
prepared, each blot contained from 0.1 pg to 1.0 mg of one of 
five cathepsin cDNAs. Each blot was hybridized with each 
corresponding 32P-labeled cathepsin cDNA probe and wished as 
described above. The results indicated that the assay was 
sufficiently sensitive so as to detect as little as 10 pg of 
the corresponding unlabeled cathepsin cDNA with overnight 
autoradiographic exposure. 
Quantification of mRNA. 
The RNA dot blot procedure was used to quantify each 
specific cathepsin mRNAs. Total RNA from normal tissues and 
tumors were dissolved in denaturation buffer (Ral et al, 1987) 
and heated at 65°C for 10 min. The denatured RNA solutions 
were diluted with 20 x SSC and varying amounts (0.5 µg to 10 
µg) were spotted on nitrocellulose filters. After 
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hybridization (Bell et al, 1981) with the appropriate nick-
translated 32P-labeled cDNA insert (approx. 5 x 108 cpm/µg), 
the filters were washed with 0.1% SDS in 0.1 x SSC at room 
temperature for 1 hr and at 55°C for a second hr. The 
intensity of the hybridization signal was determined by 
densitometry (LKB Ultrascan SL Enhanced Laser Densitometer) 
after autoradiography. 
Northern Blot Analysis 
Total RNA or poly(A)+ RNA was denatured with glyoxal and 
dimethylsulfoxide and subjected to electrophoresis in a 1.2% 
agarose gel (Maniatis et al, 1982). The samples were 
transferred to a nitrocellulose filter (Maniatis et al, 1982) 
and the filter was hybridized as described above. 
Southern Blot Analysis 
High molecular DNA were extracted from both normal mouse 
liver and Bl6a melanoma (Maniatis et al, 1982). 20 µg DNA for 
each sample was digested with restriction enzyme(s) at 37°C 
over night. The digested DNA was electrophoresed in O. 6% 
agarose gel. The gel was denatured in a solution of 1.5 M 
NaCl, 0.5 M NaOH for an hour and neutralized in a solution of 
1.5 M NaCl, 0.5 M Tris, PH 7.4 for another hour. The samples 
were then transferred onto nitrocellulose filter (Maniatis et 
al, 1982) and the filter was hybridized as described above 
(Bell et al, 1981). 
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~asurements of Metastatic Potential 
The metastatic potential of the murine melanoma variants 
(Fidler, 1973, 1978a and 1978b) were determined using both an 
intravenous lung colonization assay and a subcutaneous model 
of spontaneous metastasis as described by Schultz, et al 
(1988). Monodispersed tumor cells {l x 105 cells/animal) were 
obtained from secondary cultures of B16-Fl, B16-F10 and B16a 
melanomas and injected intravenously through the tail vein of 
syngeneic host mice or subcutaneously in their right axillary 
region. After 18 days the mice were sacrificed and examined 
for disseminated tumor colonies. The lungs were removed, 
washed with PBS, stained with Bouin's fixative and the visible 
tumor colonies counted. 
Construction of a Mouse Melanoma cDNA Library 
The mRNA used for construction of the cDNA library was 
prepared from mouse Bl6a melanoma (Division of Cancer 
Treatment Tumor Depository, National Cancer Institute-
Frederick Cancer Research Facility, Frederick, MD). cDNA was 
synthesized following the protocol of Gubler and Hoffman 
{1983) with minor modification. Poly(A)+ RNA (5 µg) was 
reverse-transcribed by avian myeloblastosis virus reverse 
virus transcriptase (Life Science) with oligo dTc 12_18> as 
primer. The first-strand heteroduplex was converted to fully 
double-stranded cDNA by using DNA polymerase I (BRL) and 
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Figure 2. Scheme for Construction of a B16a Melanoma cDNA 
Library 
Poly(A) + RNA was reverse-transcribed by avian 
myeloblastosis virus reverse transcriptase, with oligo dT< 12_ 
as primer. The first-strand heteroduplex was converted to 
18) 
fully double-stranded cDNA by using DNA polymerase I and RNase 
H. The double stranded cDNA was then methylized with Eco RI 
methylase followed by Eco RI linker addition. After digestion 
with Eco RI, the cDNA was inserted into vector Eco RI site. 
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Figure 2. Scheme for Construction of a Bl6a Melanoma cDNA 
Library 
AAAA m.RNA from B16a 
l TTIT RTase 
AAAA 
TTIT 1st strand 
l RNase H DNA Pol I 
2nd strand 
l T4 DNA Polymerase 
l EcoRI Hethylase 
RI 
l 
I CH3 ~ Eco RI Linker ' . . 
Ligase 
~ ~ 
1 EcoRI 
~ ~ 
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RNase H (BRL). The double stranded cDNA was then methylized 
with Eco RI methylase followed by Eco RI linker addition (Fig. 
2). After digestion with Eco RI and size fractionated through 
a sepharose CL-4B column the cDNA with the sizes over 600 bp 
was selected and then inserted into AgtlO vector (Promega) Eco 
RI site. The library was plated on ~ coli 600 ~HFI cells. 
The titer indicated the library has a complexity of 100,000. 
screening a Melanoma cDNA Library and Sequencing 
Phage-plaque replicas from melanoma AgtlO library were 
prepared by the method of Woo (1979) and nitrocellulose 
filters (Schleicher and Schuell) replicas were prehybridized 
and hybridized as the procedure described previously (Qian et 
al, 1989). DNA probes were labeled with a-32P-dCTP (3, oooci/-
mmole, Amersham) using either a nick-translation kit (Ame-
rsham) or a random priming kit (IBI). The positive clones 
were then further purified. The purified clones were restric-
tion-mapped and the inserts were subcloned into plasmid vector 
PGEM-4Z followed by sequencing. 
PCR (Polymerase Chain Reaction) was also used in 
screening the cDNA library. In order to get further S'-end 
sequence )\.gtlO forward or reverse primer (Biolabs) was used 
as sense primer while oligonucleotide designed according to 
known 5' -end cathepsin B sequence were used as antisense 
primer. The library phage lysate was used as templet 
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Figure 3. Scheme for Screening the B16a melanoma cDNA Library 
by PCR for 5 1 -End of cDNA 
7'.gtlO forward or reverse primer was used as sense primer 
while oligonucleotide designed according to known 5'-end 
cathepsin B sequence were used as anti sense primer. The 
library phage lysate was used as template directly. PCR was 
carried by Taq polymerase. The reaction mixtures were 
extracted with chloroform and the amplified DNAs were polished 
with T4 DNA polymerase and ligated into the Sma I sites of 
pGEM-4Z. 
Figure 3. Scheme for Screening the B16a melanoma cDNA Library by PCR for 5'-End of cDNA 
---+ Forward Primer 
Reverse Primer 
..,.... Insert S' Primer 
l ,Taq Polymerase PCR 
l. T4 DNA Polymerase T4 DNA Ligase 
cDNA Library 
in Vector 
A,.gtlO 
5'-End cDNA Library 
in Vector PGEM-4Z 
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directly. The reaction solution contained 10 mM Tris-HCl, PH 
g.3, 50 mM KCl, 1.5 mM MgC1 2 0.001% (W/V) gelatin, 1 mM dNTP 
(dATP, dCTP, dCTP and TTP), 100 pmole each primer, 109 phages 
and 2.5 u Taq polymerase (Perkin Elmer Cetus). The reactions 
were carried out on 100 µl solution for 30 cycles under the 
condition of 94°C, 1 min; 55°C, 2 min; 70°C, 3 min. The 
reaction mixtures were extracted with chloroform and amplified 
oNAs were subcloned into the Sma I site of pGEM-4Z (Fig. 3). 
Plasmids with cathepsin B DNA inserts were identified by 
colony hybridization (Maniatis,1982) with 32P-labeled internal 
oligonucleotide and then sequenced. 
The double strand sequencing was carried out with either 
general primers (Sp6 and T7 primers, promega) or designed 
oligonucleotides as primers using dideoxy chain-termination 
method of Sanger et al (1980) with modification essential for 
double-stranded sequencing as described by Chen and Seeburg 
(1985). The double strand DNA was first denatured with 0.2 
M NaOH and then sequenced with sequenase (USB) and 35S-dATP. 
Isolation of Mouse Cathepsin B Gene 
Mouse embryo genomic and a NIH3T3 cell genomic libraries 
were screened by hybridization with 32P-labeled fragments of 
the mouse cathepsin B cDNA (Chan et al, 1986). Phages 
containing fragments of the mouse cathepsin B gene were plaque 
purified. Phage DNA was prepared and DNA fragments containing 
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sequences of the gene identified by Southern blotting. 
Appropriate fragments were isolated and subcloned into plasmid 
pGEM-4Z. A series of oligonucleotides were designed as 
primers according to the cDNA sequence and were used for 
sequencing the gene. The inserts in plasmids were sequenced 
and the sequences were analyzed with DNASTAR program (DNASTAR, 
INC) . 
Despite repeated attempts, a DNA fragment containing 
sequences of exon 7 to intron 8 could not be cloned by 
screening the two genomic libraries. I am able to isolate 
this fragment using a PCR procedure. The PCR reaction of 100 
µl contained 10 mM Tris-HCl, pH 8.3, 50 mM KCl, 1.5 mM MgC1 2 , 
0.001% gelatin, 1 mM dNTP, 100 pmole each primer, either 109 
phages from the genomic libraries or 1 µg mouse kidney genomic 
DNA and 2.5 unit Taq polymerase (Cetus). PCR was carried out 
for 30 cycles under the conditions of 94°C, 1 min., 55°c, 2 
min. , 7 o0c, 3 min. The PCR products were analyzed by electro-
phoresis in agarose gels. First I tried to use one pair of 
oligonucleotides corresponding to positions of amino acids 
190-196 in exon 7 (sense primer 1) and an oligonucliotide 
(antisense primer 1) in intron 8. It failed to generate any 
product when using either phage genomic libraries (Fig.4, 
lane 6) or mouse kidney genomic DNA (Fig. 4, lane 7) as 
templates. The procedure was thus performed using two pairs 
of oligonucleotides as primers: one pair corresponded to 
positions of amino acids 190-196 in exon 7 (sense primer 1) 
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Figure 4. Using PCR Procedure to Clone Exon 8 Region 
s. 
Lane 3, 5 and 7: genomic libraries were used as templet-
Lane 1, 4 and 6: mouse kidney genomic DNA was used as 
temp lets. The primers for lane 1 and 3 are from ex on 8 (sense 
primer 2) and intron 8 (antisense primer 1). The primers for 
lane 4 and 5 are from exon 7 (sense primer 1) and exon 8 
(antisense primer 2). The primers for lane 6 and 7 are from 
exon 7 (sense primer 1) and intron 8 (antisense primer 1). 
Lane 3 is DNA markers (AHindIII and ~x174 HaeIII). 
The direction of each primer is shown as following: 
Exon 7 (Missing Gene Portion) Intron 8 
.. .. .. 
Sen.Primerl Sen.Primer2 An.Primer2 An.Primer! 
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Figure 4. Using PCR Procedure to Clone Exon 8 Region 
1 2 
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and amino acids 257-262 (antisense primer 2) in exon 8; the 
second pair consisted of a primer corresponding to position 
amino acid 227-232 in exon 8 (sense primer 2) and the an-
tisense primer 1 from intron 8. Both pairs failed to work 
when using phage genomic libraries as templets (Fig. 4, lane 
3 and 5), however, they both worked well when using mouse 
kidney genomic DNA as templates and produced a 500 bp and a 
750 bp band (Fig. 4, lane 1 and 4). So the earlier difficulty 
encounterd may be due to presence of secondary structure which 
prevents the construction of this fragment into libraries and 
its synthesis by Taq polymerase when using the first pair of 
primers. The PCR products were isolated and cloned into the 
Sma I site of pGEM-4Z. The positive colonies were identified 
by hybridization with 32P-labeled appropriate oligonucleotides 
(Maniatis, 1982). The inserts in the plasmids were sequenced 
directly using SP6, T7 or designed oligonucleotide primers. 
PCR was also used to determine the distances between adjacent 
exons and introns. The templates were either phage DNA, 
plasmid DNA containing cathepsin B gene sequences (100 ng) or 
mouse kidney genomic DNA (1 µg). 
Rapid Amplification of cDNA Ends CRACE) 
Because our mouse cathepsin B cDNA lacked the region 
encoded by exon 1, I used RACE methods essentially as 
described by Frohman et al (1988), with modification. 
Briefly, the first strand cDNA was prepared from 5 µg mouse 
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kidney total RNA by using an oligonucleotide primer 
complimentary to a 5'-end sequence in mouse cathepsin B cDNA 
and avian myeloblastosis virus reverse transcriptase. The 
resulting first strand cDNA was tailed with dATP and terminal 
deoxynucleotide transferase. The second strand cDNA was 
synthesized with oligo(dT)-adaptor as primer and klenow 
enzyme. The double strand cDNA was amplified with PCR using 
the adaptor as sense primer and another internal oligonucleo-
tide as antisense primer. The PCR was carried out for 30 
cycles (94°C, 1 min, 60°C, 2 min, 10°c, 2 min). The product 
was polished with T4 polymerase and subcloned into PGEM-4Z Sma 
I site followed by analysis and sequencing (Fig. 5). 
Primer Extension and RNA Protection 
The primer extension procedure was as following: 5 µg of 
total RNA or 2 µg of poly(A) RNA from mouse kidney and 1 pmol 
of the 32P-labeled oligonucleotide 5 1 -GGAGCCGCTCCTGGCCTC-3', 
complementary to nucleotides 48 to 65 of the mRNA, were 
hybridized and extended with 'AM'./ reverse transcriptase (Life 
Science) as described by Gil et al (1987). The primer-
extended products were separated on a 8% polyacrylamide/8 M 
urea gel. A sequencing reaction was performed using the same 
oligonucleotide as above as primer and a 5' upstream fragment 
of the mouse cathepsin B gene as a template. The sequencing 
reaction was loaded on the gel at the same time as primer 
extension reaction was loaded. 
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RNA protection assay was a modification of the procedure 
by Little et al (1987). A 241 bp Pst I DNA fragment (from 
nucleotide -156 to 85 bp) of mouse cathepsin B gene was 
cloned into pGEM-4Z. This plasmid (pmGB250) was linearized 
with Hind III and a radioactive antisense RNA probe was 
synthesized using the Riboprobe Gemini II Core System 
(Promega), T7 RNA polymerase, and a-32P-UTP. In vitro 
synthesized RNA was incubated at 45°C overnight with 40 µg 
total RNA in 30 µl of hybridization buffer (80% Formamide/40 
mM Pipes, pH 6.7/400 mM NaCl/l mM EDTA). Then 300 µl of a 
solution of 10 mM Tris Cl, pH 7.5/5 mM EDTA/300 mM NaCl/ 40 
µg/ml RNase A/ 2 µg/ml RNase Tl was added and incubated at 
30°C for 60 min. The protected fragments were analyzed on a 
8% polyacrylamide/8 M urea gel. A sequencing reaction was 
performed with a 5' upstream fragment of the mouse cathepsin 
B gene as a template and an antisense oligonucleotide 
(5'-CCTGCAGCCACCAAGCCA-3') corresponding to nucleotides +86 
to +69 from transcription start site as a primer. since there 
happen to be a nucleotide c, adjacent to the Pst I site in the 
vector pGEM-4Z, which is identical to the nucleotide C 
adjacent to the Pst I site in the gene fragment cloned into 
pGEM-4Z at position +86 of the mRNA, this primer started from 
+86 instated of +85 should have the same 5' end as the 
protected 32p-cRNA fragment does. The sequence generated by 
this primer indicates the sequence of the protected mRNA 
fragments. The sequencing reaction was loaded at the same 
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time when the RNA protection reactions were loaded. 
Measurement of mRNA Half Life 
NIH3T3 fibroblasts, B16Fl and B16a cells ( 24 flasks 
each) were grown in MEM (Eagles's Minimum Essential Medium) 
supplemented with non-essential amino acids plus Fetal Calf 
serum (heat inactivated). Just prior to confluence the medium 
was replaced and 5 µg/ml Actinomycin D was added. In group 
of 4 flasks cells were subjected to the treatment for o, 1, 
3, 5, 7 and 12 hours. After each period of the treatment, the 
medium was discarded and the cells were washed with PBS, 
trypsinized and suspended in PBS. Then the cells are pelleted 
by centrifugation 3,000 RPM for 5 min. The supernatant was 
discarded and 2 ml of PBS was added. The cells were frozen 
in liquid nitrogen. 
The total RNAs were extracted from each group of cells. 
RNA dot blot and Northern blot were performed by hybridization 
with mouse cathepsin B cDNA inserts and autoradiographed as 
described above. The autoradiographies were subjected to 
densitometer scanning analysis. Relative dot intensity 
readings were plotted as a function of the time of 
transcription inhibition by actinomycin D. mRNA half-lives 
were determined by a least-squares linear regression 
calculation of the plotted data. 
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Figure 5. Scheme for Rapid Amplification of 5'-End of cDNA 
{5'-RACE) 
The first strand cDNA was prepared from 5 µg mouse kidney 
total RNA by using an oligonucleotide primer complimentary to 
a 5 •-end sequence in mouse cathepsin B cDNA or oligo {dT12_18 ) 
and avian myeloblastosis virus reverse transcriptase. The 
resulting first strand cDNA was tailed with dATP and terminal 
deoxynucleotide transf erase. The second strand cDNA was 
synthesized with oligo(dT)-adaptor as primer and klenow 
enzyme. The double strand cDNA was amplified with PCR using 
the adaptor as sense primer and another internal 
oligonucleotide as antisense primer. The PCR was carried out 
and the PCR product was polished with T4 polymerase and 
subcloned into PGEM-4Z Sma I site followed by analysis and 
sequencing. 
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yiqure 5. Scheme for Rapid Amplification of 5 1 -End of cDNA 
(5 1 -RACE) 
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Figure 6. Scheme for Primer Extension Assay 
RNA 
+---« Primer 
RTase 
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• 
Denature 
Electrophoresis 
32P-labeled oligonucleotide were hybridized with total RNA 
or poly(A)+ RNA and extended with AMV reverse transcriptase. 
The primer-extended products were denatured and separated on 
a 8% polyacrylamide/8 M urea gel by electrophoresis. 
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Figure 7. Scheme for RNA Protection Assay 
A DNA fragment containing 5'-end of the gene was cloned 
into pGEM-4Z. This plasmid was linearized and a radioactive 
antisense RNA probe was synthesized using the Riboprobe Gemini 
II Core System (Promega), SP6 or T7 RNA polymerase, and a-
32p-UTP. In vitro synthesized antisense RNA was incubated with 
total mouse kidney RNA for annealing. RNase A and RNase Tl 
was added to digest single strand RNA. The protected 
fragments were denatured and analyzed on a 8% polyacrylamide/8 
M urea gel by electrophoresis. A sequencing reaction was 
performed with a 5 1 upstream fragment of the mouse cathepsin 
B gene as a template and an antisense oligonucleotide 
(5'-CCTGCAGCCACCAAGCCA-3 1 ) corresponding to nucleotides +86 
to +69 from transcription start site as a primer which has the 
same 5 ' end as the protected 32P-cRNA does . The sequence 
generated by this primer indicates the sequence of the 
protected mRNA fragments. The sequencing reaction was loaded 
at the same time when the RNA protection reactions were loaded 
to the gel. 
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Figure 7. Scheme for RNA Protection Assay 
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CHAPTER IV 
RESULTS 
cathepsin H Cloning and Seguencing 
To identify the cathepsin H cDNA mixed chemically 
synthesized DNA probes were designed on the basis of the amino 
acid sequence of the mature enzyme. The oligonucleotides were 
synthesized corresponding to residues F-136 to K-148 of rat 
cathepsin (Takio et al, 1983). This sequence was chosen due 
to its low degeneracy. A 20 mer and 27 mer were synthesized 
as following: 
C A 
20 mer: TTTGCCTTTGAGGTCACCGA 
27 mer: CAGTGGCTTCTAAAATACTACATATTT 
C G G G C 
The two strands produce an 8 bp overlap in middle of the 
sequence. The 20 mer and 27 mer were then annealed and filled 
in with dNTP and a-32P-dCTP using DNA polymerase (klenow) after 
first being r-32P-labeled with ATP using T4 Polynucleotide 
kinase. Since they were double labeled, the probes had very 
high specific activity (10 10 cpm/µg). Five clones were 
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Figure 8. Restriction Map of Rat cathepsin H cDNA (RHCll) 
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The open boxes indicate coding region including partial 
prepeptide (pre), total propeptide (pro) and total mature 
protein (cathepsin H). 3'-untranslated region was indicated 
as 3'-UTR. The restriction sites were indicated as shown. 
Arrow lines show the strategy used to determine the nucleotide 
sequence. 
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rsolated after screening 106 plaques. They partially overlap 
to each other. 
hRHCll (Fig. 8) 
The restriction map of the longest clone 
shows that the insert is 1.4 Kb long. 
sequence analysis disclosed the presence of a contiguous open 
reading frame extending beyond the amino terminus of mature 
cathepsin H. This indicates that as expected, mature 
cathepsin H is contained within a larger precursor protein, 
which includes pre- and pro-peptides at the N-terminus. But 
unlike cathepsin B, there is no carboxyl-terminal extension 
in cathepsin H (Fig. 9). Comparison of the sequence and the 
mixed oligonucleotide probes (39 mer) designed for screening 
showed a perfect match except for two base pairs. On Northern 
blot analysis of 10 different rat tissues (Fig. 10, lane 3-13) 
the CRHll insert specifically hybridizes to an mRNA of 1.6 kb, 
which is a little larger than the RCHll 1.4 kb cDNA insert 
(Fig. 10, Lane 1). A summary of characteristics of rat pro-
and mature cathepsin H is shown in Table 4. 
Expression of Cathepsin H mRNA in 10 Normal Rat Tissues 
To further quantify cathepsin H mRNA in different 
tissues, RNA dot blot was performed with RCHll 1.4 bp insert 
as probe. The dot blot results are shown in Fig. lla. The 
experiment was repeated three times. The yeast tRNA was used 
as a negative control. To rule out the possibility of cross 
reaction between cathepsin H and other cathepsins, all five 
cathepsin cDNAs were dotted onto filters in the same doses 
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Table 4. Summary of Characteristics of RAT Pro- and Mature 
cathepsin H 
PROCATHEPSIN H CATHEPSIN H 
Amino Acid Residues 313 220 
Molecular weight 35,079 daltons 24,001 daltons 
Cysteines 9 8 
Isoelectric point, pI 8.47 6.57 
Potential glycosylation 
sites 3 1 
Predicted secondary structure 
(CHOU-FASMAN) 51% helix 513 helix 
66~ extended 691. extended 
471. turn 52'9 turn 
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Figure 9. Nucleotide and Predicted Amino Acid Sequence of Rat 
Preprocathepsin H cDNA (RCHll). 
-100 l -90 
-110 
Ala 
GCG 
pro Leu 
CCC CTG 
Cys Ala 
TGC GCT 
Gly Ala Trp Leu Leu 
GGG GCC TGG CTG CTG 
Ser Ala Gly 
AGT GCT GGG 
Thr Ala Glu Leu Thr Val Asn Ala Ile Glu Lys P(le His Phe 
ACC GCT GAG CTG ACC GTG AAT GCC ATA GAA AAG TTT CAC TTT 
-BO 
Thr Ser Trp 
ACG TCA TGG 
-50 
Gln Ala 
CAA GCC 
-70 -60 
Lys Gln His Gln Lys Thr Tyr Ser Ser Arg Glu Tyr Ser His Arg Leu Gin Val Phe Ala Asn Asn Trp Arg Ile 
AAA CAG CAT CAA AAG ACG TAC AGC TCG AGG GAG TAC AGC CAC AGG CTG CAG GTG TTT GCC AAC AAC TGG AGG ATT 
-40 -30 
Asn Gln Arg Asn His Thr Phe Lys Met Gly Leu Asn Gln Phe Ser Asp Met Ser Phe Ala Glu Ile Lys His Lys Tyr Leu 
AAC CAG AGG AAC CAC ACA/ rTT AAA ATG GGA TTG AAC CAG TTT TCA GAT ATG AGC TTT GCC GAA ATA AAA CAC AAA TAC CTC 
-10 l 10 
-20 
Trp 
TGG 
Glu Pro Glr Asn Cys Ser Ala Thr Lys Ser Asn Tyr Leu 
GAG CCT CAG AAT TGC TCA GCC ACC AAA AGT AAC TAC CTC 
Gly Thr 
GGT ACT 
Pro -!'yr Pro Ser Ser Met Asp 
CCC TAC CCA TCC TCC ATG GAC 
/Hg Lys 
AGG AAG 
20 30 
GlY Asn Val val Ser Pro Val Lys Asn Gln Gly Ala Cys Gly Ser Cys Trp Thr Phe Ser Thr Thr 
GGA AAT GTC GTT TCA CCA GTG AAG AAC CAG GGG GCC TGT GGC AGC TGC TGG ACT '!'TC TCA ACC ACT 
50 60 
Ile Ala Ser Gly Lys Met !!et Thr Leu Ala Glu Gin Gin Leu Val Asp Ala Gln Asn Phe Asn 
ATT GCC AGT GGG AAA ATG ATG ACC TTG GCT GAG CAG CAG CTG GTG GAT GCC CAG AAC '!'TC AAC 
80 90 
Gly Ala 
GGG GCC 
Asn His 
AAT CAT 
40 
Leu Glu Ser Ala Val Ala 
CTA GAG TCA GCT GTT GCT 
70 
Gly Cys Gln Gly Leu 
GGC TGC CAA GGT CTC 
100 
Lys Asn Gly Gln Cys Lys 
180 
H:G 
pro Ser Gln Ala Phe Glu Tyr Ile Leu Tyr Asn Lys Gly Ile Met Gly Glu Asp Ser Tyr Pro Tyr Ile 
CCC AGC CAG GCC TTC GAG TAC ATC CTG TAC AAC AAG GGC ATC ATG GGA GAG GAC AGC TAC CCT TAC ATA AAG AAT GGT CAG TGC AAA o JO 
110 120 130 
Phe Asn Pro Glu Lys Ala Val Ala Phe Val Lys Asn Val Val Asn I e T r ·,eu Asn Asp Glu Ala Ala Met Val Glu Ala Val Ala Leu 
TTC AAC CCA GAA AAG GCC GTC GCG TTC GTC AAG AAT GTT GTC AAC ATC ACAICTC AAT GAT GAG GCT GCA ATG GTA GAG GCT GTG GCC CTA 
140 150 160 
Val Tyr Ser Ser Asn Ser Cys His Lys Th! Asn Pro Val Ser Phe Ala Phe Glu Val Thr Glu Asp Phe Met Met Tyr Lys Ser 
AAT CCT GTG AGC TTT GCC TTT GAG GTG ACT GAA GAT TTT ATG ATG TAT AAA AGT GTC TAC TCC AGT AAC TCC TGT CAT AAA ACT bl\ 
170 180 190 
Pro Asp Val Asn His Ala val Leu Ala Val Gly Tyr Glu Asn Gly Leu Leu Tyr Ile Val Lys Asn Ser Trp Gly 
CCA GAT GTA AAC CAT GCA GTC CTG GCT GTT GGC TAT GAA AAT GGA TTA CTC TAC ATT GTG AAA AAC TCT TGG GGC YOO 
200 210 220 
Asn Gly Asn Asn Gly Tyr Phe Leu Ile Glu Arg Lys Asn Met Cys Leu Ala Ala Cys Ala Ser Tyr Pro Ile Pro Gln Val 
/\AC GGG AAC AAT GGG TAC TTC CTC ATT GAG CGT AAG AAC ATG TGT CTG GCT GCC TGT GCC TCC TAC CCC ATC CCT CAG GTA 
220 
oc ~ 
TAA GCCACGJCTGCACAGGCCAACTGCTTGGCAGACAAAGGGAGGAACTGGTCCTACGATGAGAATGCCGCCCTGGAGAAAGTTGTTCAGAAATTCACCCAGAGGCCCTCTCACTCCTGA 111 
GTCTAGACGCCTAAAGACAAGTAAGGAAGAACTTGACCAGCAACAAGCCCGCC~GTGTGACGACATCACCAGCCATACGCTTTGTTTGllATATGGTTTTTAAATGACCCAAAACCATGTG 
GACCTACAATCTTCTCTTTTCAGCTCTCTTCATATAGGCAAAGCTCCGATGGCTACCTTTTCTATGTTGTATATT~~T~ii/l'GCAGTGAACGCCTGCCTGGGCTGGGCCTAGACC : }4t 
The arrows indicate potential cleavage sites for post-
translation processing. The boxes indicate potential 
glycosylation sites and polyadenylation signal. The underline 
indicates the sequence initially chosen for the preparation 
of the synthetic oligonucleotide probe. The triangles 
indicate the nucleotide differences from a published rat 
cathepsin H cDNA sequence (Ishidoh et al, 1987a). 
Figure 10. Northern Blot of Total RNA from Rat Tissues. 
with Cathepsin H cDNA as Probe 
bp 
23, 130-
9,419-
6,557-
4,371-
2,322-
2,028-
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The amount of RNA applied was 20 µg per well. 
Hybridization was performed with a 32P-labeled mouse cathepsin 
H insert. RNA was isolated from rat liver (lane 3), spleen 
(lane 4), kidney (lane 5), pancreas (lane 6), heart (lane 7), 
testis (lane 8), lung (lane 9), uterus (lane 10), brain (lane 
11} and thymus (lane 12). Lane 1 is cathepsin H cDNA (RCHll, 
5 ng} . Sizes of DNA molecular markers are indicated on the 
left side as base pairs. 
(0 .1 ng) • 
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The results showed only cathepsin H cDNA had a 
positive signal, indicating that the probe is very specific. 
There is no any cross hybridization between cathepsin H and 
other cathepsins. Dot blot analysis showed kidney had highest 
cathepsin H mRNA level, in contrast, pancreas had very low 
level of cathepsin H. The distribution of the m.RNA was quite 
uneven in various tissues. There was an over 50 fold 
variation in cathepsin H m.RNA levels among the 10 rat 
tissues measured by densitometry scanning. 
To compare the tissue distribution of cathepsin H m.RNA 
with the other four cathepsin mRNAs, RNA dot blot analyses 
were also performed with cathepsin B, D, L and S cDNA probes 
(Fig. llB-F). The comparison revealed a common feature in 
distribution of the five cathepsin mRNA: All of them had 
relatively high m.RNA level in the lung and/or kidney while low 
level in the pancreas. On the other hand, there were marked 
differences in the distribution of the five cathepsin mRNAs. 
For instance, spleen contained relatively high level of 
cathepsin B, D, H and s, but very low level of cathepsin L 
(almost undetectable). Heart contained considerable level of 
cathepsin B, D and s, but very low level of cathepsin H and 
L. In contrast, liver contains considerable cathepsin H and 
L but very low level of cathepsin B, D and s. Table 5 
summarizes the relative levels of the five cathepsin mRNAs. 
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Expression of Five Cathepsin mRNAs in Rat Walker-256 
carcinosarcoma 
Five cathepsin mRNA expression in Rat Walker-256 
carcinosarcoma was examined. Since kidney and/or lung have 
relatively higher levels of all five cathepsins, they were 
used as control tissues. RNA dot blot experiments were 
performed and the densities of dots were scaned by 
densitometry. The results are shown in Fig. 12. The results 
revealed among five cathepsins, only cathepsin B had elevated 
expression compared to the kidney (over 2 fold) . 
Expression of Cathepsin mRNAs in Murine Normal Tissues and 
Melanoma Variants 
Agarose gel electrophoresis of total RNA isolated from 
eight mouse normal tissue and three murine melanoma variants 
was performed following denaturation with glyoxal and 
dimethylsulfoxide. The integrity of the 18S and 28S ribosomal 
RNA indicated that the isolated RNA was largely intact. These 
RNAs were used in dot blot experiments. 
Figure 13 shows the results by densitometry scans 
obtained after dot blot analysis of total RNA isolated from 
normal mouse tissues and a yeast tRNA standard which serves 
as a negative control using cDNAs of cathepsin B, D, H, L and 
s as probes, respectively. It is evident that the five 
lysosomal cathepsin mRNAs are very differently distributed 
among the normal mouse tissues. Kidney shows the highest 
Figure 11. RNA Dot Blot Hybridization Analysis with cDNA 
Probes for cathepsin H, B, D, L and s 
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The different rat tissues from which total RNA was 
isolated are indicated on the top of the figure. The RNA 
doses used varied from O. o 5 µg to 5. o µg. To verify the 
specificity of the probes, the cDNA inserts for all five 
cathepsins were applied to the right hand land of each filter. 
Figure 11. RNA Dot Blot Hybridization Analysis with cDNA 
Probes for Cathepsin H, B, D, L and S 
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Table 5. Relative Levels of Cathepsin mRNAs in Rat Tissues 
Tissue H B D L s 
------------------------------------------------------
Kidney 100 (100) 100 100 100 100 
Lung 95 (38) 97 169 44 495 
Liver 77 (40) 43 27 57 115 
uterus 73 88 99 47 470 
Spleen 67 (34) 83 60 9 500 
Heart 27 (6) 72 99 53 41 
Testis 23 (4) 44 36 40 90 
Brain 12 (2) 75 89 11 480 
Thymus 7 35 41 10 134 
Pancreas 2 30 10 9 20 
mRNA levels of various lysosomal cathepsins were 
determined by dot blot analysis of total RNA (up to 5 µg). 
Following autoradiography, the intensity of the dot signals 
was quantified by densitometry and the results were normalized 
to kidney as 100%. The numbers in brackets are relative 
levels of immunoreactive cathepsin H (Kominami et al, 1985) 
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Figure 12. Relative m.RNA Levels of Five Cathepsins in Rat 
Lung, Kidney and W-256 Carcinosarcoma 
Total RNA was extracted from the tissues and tumor, dot 
blotted onto nitrocellulose filters and hybridized with 
specific cDNA probe as indicated in each panel. The 
intensities of hybridization signals were determined by 
densitometry and are given in arbitrary units. In each case, 
the corresponding lung cathepsin mRNA level was set to 10. 
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Figure 12. Relative mRNA Levels of Five Cathepsins in Rat 
Lung, Kidney and W-256 Carcinosarcoma 
3;000~~~~~~~~~~~~~~~~-L un g Kidney W-256 D D VZ1 Cathepsin H 
Cathepsin B 
Cathepsin D 
Cathepsin L 
Cathepsin S 
Figure 13. Relative Levels of mRNA for Five Lysosomal 
Cathepsins in Normal Mouse Tissues 
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Up to 10 µg of total RNA isolated from normal tissues was 
denatured and spotted onto a nitrocellulose filter. After 
hybridization under high stringency conditions with 
nick-translated cDNA inserts, the washed filters were 
autoradiographed. Each panel is result of scanning the dot 
signals with densitometry. Cathepsin cDNA probes used for 
hybridization are indicated on right side. 
Figure 13. Relative Levels of mRNA for Five Lysosomal 
Cathepsins in Normal Mouse Tissues 
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expression of cathepsin Band cathepsin H mRNAs, heart has the 
highest level of cathepsin D mRNA, and lung shows the highest 
levels of cathepsin L and cathepsin s mRNAs. Pancreas has 
significant levels of cathepsins D and L mRNAs and barely 
detectable levels of cathepsin B, H, and s mRNAs. 
The metastatic potential of three murine variants (B16a, 
Bl6Fl0 and Bl6Fl) are quite different as shown in Table 6. 
Figure 14a shows the dot blot results of cathepsin B mRNA 
levels in the solid tumors of the three melanoma variants. 
Cathepsin B mRNA level in Bl6a was about 6 times higher than 
Bl6-Fl and 4 times higher than Bl6-Fl0. Because physical 
inspection of the tumors produced by the three melanomas 
revealed differences in their texture and appearance, I am 
concerned that variations in cathepsin B levels could reflect 
differences in vascularization and infiltration by 
inflammatory cells such as macrophages. However, Figure 14b 
reveals that this is not the case, as identical results were 
also obtained using secondary cultures of the three melanoma 
variants. The same RNAs were used in Figure 14c and a chicken 
actin was used as the hybridization probe, the result 
indicates the amounts of the total RNA on the filter for each 
variant of the melanomas are the same. When the other four 
cathepsin (D, H, L and S) cDNAs were used as probes, their 
expression levels showed no significant differences among 
these three variants (Fig. 15). Figure 16 shows the 
densitometry result of cathepsin B expression in three 
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variants and normal mouse kidney and liver. 
A summary of relative mRNA levels of the five cathepsins 
in the three melanoma variants is shown in Figure 17. The 
results were obtained from densitometric scans after a similar 
dot blot analysis of total RNA from secondary cultures of the 
three melanoma variants. Only cathepsin B mRNA levels are 
greatly increased in the highly metastatic B16a subcutaneous 
tumors, whereas the other four lysosomal proteinases show no 
differences in mRNA expression level among the three melanoma 
variants. 
Table 7 summarizes the relative levels of cathepsin B 
mRNA in the eight normal mouse tissues and in the three B16 
melanoma variants normalized to kidney as 100%. Compared to 
kidney, which was the tissue possessing the highest level of 
cathepsin B among the eight normal mouse tissues studied, the 
cathepsin B mRNA level in B16a was 3.6 fold higher. 
Northern Blot Analysis of Cathepsin B mRNA in Normal Mouse 
tissues and Bl6 Melanoma Variants 
Northern blot analyses of total RNA and poly(A)+ mRNA 
from normal mouse tissues revealed a single 2.2 kb band. 
However the three melanoma variants, in addition to the 2.2 
kb transcript, expressed another two mRNA transcripts, 4 kb 
and 5 kb, which hybridized with the probe under high 
stringency wash conditions. A typical blot result is shown 
in Figure 18. The ratios of 5 kb, 4 kb and 2.2 kb transcripts 
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Table 6. Assay of Metastatic Potential in 
Murine Melanoma Variants 
MELANOMA VARIANTS COLONIES COLONIES 
s.c. I. v. 
F1 0-1 10-30 
F10 2-3 50-150 
8 t6a 100+ 300+ 
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Figure 14. RNA Dot Blot Hybridization Analysis of Three Bl6 
Melanoma Variants with Mouse Cathepsin B cDNA 
a b c 
8160 Fio F1 8160 F10 F, 8160 F10 F, 
10µ.g 
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·-
e 
••• 5 
• • • e • • •• 2 e • eee e e • • 
0.5 
Total RNAs were isolated from solid tumors (panel a) and 
secondary cultured cells (panel b and c) of three melanoma 
variants. Panel a and b were hybridized with mouse cathepsin 
B cDNA as probe. Panel c was hybridized with chicken actin 
as probe. Dot blot hybridization and autoradiography are 
described in the Chapter III. 
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Figure 15. RNA dot Blot Hybridization Analysis of Three B16 
Melanoma Variants with Cathepsin D, H and L cDNAs 
a b c 
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Total RNAs were isolated from secondary cultured cells 
of three melanoma variants. Panel a was hybridized with a rat 
cathepsin H cDNA probe; panel b was hybridized with a human 
cathepsin D cDNA prober; and panel C was hybridized with a 
mouse cathepsin L cDNA probe. 
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Figure 16. Relative Level of mRNA for Cathepsin B in Murine 
Melanoma Variants and Normal Mouse Kidney and Liver 
i 
T 
i t .. 
I iA. I; 
.L.. ..... 
Total RNAs were isolated form melanomas B16a (peak 5), 
B16F10 (peak 4), B16Fl (peak 3), and normal kidney (peak 2) 
and liver (peak 1). Up to 10 µg of total RNA isolated from 
each tissue was denatured and spotted onto a nitrocellulose 
filter. After hybridization under high stringency condition 
with nick-translated mouse cathepsin B cDNA insert, the washed 
filter was autoradiographed and the film was scanned with 
densitometer. 
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Figure 17. Relative mRNA Levels of Five Lysosomal cathepsins 
in Secondary Cultured Cells from Three Murine 
Melanoma Variants 
Total RNA was extracted from the cells, dot-blotted onto 
nitrocellulose filters and hybridized with specific cDNA probe 
as indicated in each panel. The intensities of the 
hybridization signals were determined by densitometry as 
descr·ibed in the Chapter III and are given in arbitrary units. 
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Figure 17. Relative mRNA Levels of Five Lysosomal Cathepsins 
in Secondary Cultured Cells from Three Murine 
Melanoma Variants 
80 Cathepsin B 
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Table 7. Relative Cathepsin :mRNA Levels in Normal Murine 
Tissues and in Solid Tumors Derived from Murine 
Melanoma Variants 
84 
------------------------------------------------------------
Tissues 
Normal Organs 
Kidney 
Lung 
Spleen 
Liver 
Heart 
Skin 
Brain 
Pancreas 
Melanoma Variants 
B16a 
B16-F10 
Bl6-Fl 
Relative Cathepsin B 
mRNA Levels (100%) 
100 
59 
50 
48 
44 
38 
37 
6 
362 
82 
53 
:mRNA levels of the various lysosomal cathepsins were 
determined by dot blot analysis of total RNA (up to 10 µg). 
The intensity of the dot signals were quantified by 
densitometry and the results normalized to kidney as 100%. 
85 
Figure 18. Northern Blot of Normal Mouse Tissues and Bl6a 
9,419-
6,557-
a 
-
4371--, 
2,322- -
202s--, 
564-
Melanoma with Mouse Cathepsin B cDNA 
b c d e f 
' 
- 5kb 
- -4kb 
• -2.2kb 
Total RNAs are isolated from murine kidney (lane b, 20 
µg), spleen (lane c, 40 µg), liver (lane d, 20 µg) , Bl6a 
melanoma (lane e, 10 µg) and poly (A)+ mRNA is from Bl6a 
melanoma (lane f, 2 µg). Hind III fragments of DNA labeled 
with 32P and denatured with glyoxal and dirnethylsulfoxide were 
used as standards (lane a). Hybridization was performed with 
32P-labeled mouse cathepsin B cDNA insert. 
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were approximately 1:10:40. The two larger transcripts were 
not evident in any of the eight normal tissues surveyed in 
mice even with prolonged exposure. 
Molecular Cloning of Multiple Cathepsin B mRNA in B16a 
Melanoma 
A 1, 200 bp RI fragment of cDNA which encodes for the 
mouse preprocathepsin B sequence (Chan et al, 1986) was first 
used as a probe to screen the melanoma cDNA 1 ibrary. 2 2 
positive clones were detected after screened 50,000 plaques. 
Analysis and sequence of these clones showed all these clones 
failed to give additional information beyond the normal mouse 
cathepsin B cDNA (Chan et al, 1986) • Screening a further size 
fractionated cDNA (above 2. 2 kb) library was also 
unsuccessful. RNA blot showed the three transcripts ( 2. 2, 4 . O 
and 5.0 kb) could be detected by any portions of known mouse 
cathepsin B cDNA as probes (data not shown). In order to 
obtain a specific probe which would help to clone the large 
sized cathepsin B transcripts, I cloned the mouse cathepsin 
B gene (Fig. 19) and then performed RNA blots with different 
portions of the gene as probes. A probe ( BH3. 8) which 
detected only 4.0 and 5.0 kb mRNA transcripts on RNA blots was 
used as a specific probe to screen the cDNA library again 
(Fig. 20). Six clones were isolated, four of them also 
hybridized with the 1,200 bp cathepsin B cDNA probe. 
Figure 19, The Gene Fragment for Cloning the Larger Transcripts of Mouse 
Cathepsin B mRNAs 
Bg BH 
R,_I _ _._HJ __ H_._J__._H_J _ _,H'-J---'R-1------__J_Rl---R.Ll __ --JRl : )jj RI HJ HJ fig S flH 
l 7 kh 12 kb 
Two mouse cathepsin B gene fragments (17 kb and 12 kb) were digested according 
to their restriction sites. One fragment (indicated by bold line) which hybridized 
with only the two larger transcripts (4.0 and 5.0 kb), but not the small one (2.2 
kb), was chosen as probe to further screen the melanoma cDNA library. This fragment 
is 3.8 kb long and has restriction sites-Bam HI and HindIII at its ends, therefore 
is named BH3.8. 
Figure 20. RNA Blot Hybridization Analysis of Mouse B16a 
Melanoma with Gene Fragment as Probe 
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3 µg of poly(A)+ RNA per well was denatured, 
electrophoresed through agarose and transferred onto nitrocel-
lulose filter. Lane 1: filter was hybridized with 32P-labeled 
mouse cathepsin B cDNA. Lane 2: filter was hybridized with 
a 32P-labeled gene fragment: BH3.8, which is a 3.8 kb 
Barn HI-Hind III restriction fragment corresponding to a 3'-
downstream region of the mouse cathepsin B gene. 
Figure 20. RNA Blot Hybridization Analysis of Mouse B16a 
Melanoma with Gene Fragment as Probe 
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Figure 21. Schematic Map of Mouse Bl6a Melanoma 
Preprocathepsin B cDNAs 
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>-. mB 16aCB1 
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The map was constructed from overlapping clones as shown. 
The region coding for the cathepsin B precursor is boxed. 
Restriction sites for Bam HI (Bm), Bgl II (BgII), Hind III 
(H3 ) as shown. The dotted lines indicate sites where poly(A) 
tails are added to obtain the 5.0, 4.0 or 2.2 kb transcript. 
Clones A.mB16aG4, J\.mB16aCB5 and A.mB16aCB1, each has a poly (A) 
tail as indicated by AAAA. 
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Figure 22. Nucleotide and Predicted Amino Acid Sequences of 
Mouse B16a Melanoma Preprocathepsin B cDNAs 
Arrows indicate potential cleavage sites for 
post translational processing. The potential glycosylation 
sites are underlined. The active site cysteine and histidine 
residues are circled. The complete 3 1 untranslated sequences 
are given for the 2.2, 4.0 and 5.0 kb transcripts. The 
putative polyadenylation signals are boxed. 
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Figure 22. Nucleotide and Predicted Amino Acid Sequences of 
Mouse B16a Melanoma Preprocathepsin B cDNAs 
-125 GGACCCCGGf.CGCCGCCCCTACTTN;Gf.CTCCACCGGACAGCCCACGf.CCCCCTCCC1T!'GGCTTCCTCCCTGCACCCCCAGCCTCTCGCGCTCCCC'l'CCCTCACTCCACGf.TCCACCA 
1 lo I 20 
Net Trp Trp Ser Leu Ile Leu Leu Ser Cy• Leu Leu Ala Leu Thr Ser Ah Bil A•P Ly• Pro Ser Phe Bh Pro Leu Ser Alp 
-6 TCCACC A'TG 'TGC 'T'CG TCC TTG ATC CM' CM' TCT 'TGC CTG CTC GCA CTG ACC AGT GCC CAT CAC A.AC CCT TCC TTC C\C CCG CTC TCC Gi\T 
JO 40 50 
Asp Leu Ile Aan Tyr Ile Aen Ly• Cln A1n Thr Thr Trp Cln Ala Cly Ar9 Aan· Phe Tyr Aan Val Aep Ile Ser Tyr Leu LY• Lye Leu 
85 Gi\C CTC ATT MC TAT ATC AAC AAA CAC A.AT ACA A.CA TGC CAC CCT GGA CCC A.AC TTC TAC MT GTT CA.C A.TA AGC TAT CTG A.AC .V.C CTC 
,o . 10 I eo 
Cye Cly Thr Val Leu Cly Cly Pro Lya Leu Pro Cly Arg Val Ala Phe Cly Clu Alp Ile Aap Leu Pro Clu Thr Phe A1p Ala Arg Clu 
175 TCT CGC ACT GTC CTG CGT CGA CCC AAA CTG CCA GGA AGC GT!' CCC TTC CC1' GAC Gi\C A.TA CAT CTA CCT CAA ACC TTT CAT GCA CGC ~ 
265 
355 
90 100 110 
Ciln Trp Ser Aan Cy1 Pro Thr Ile Cly Ciln Ile Arg Alp Cln Cly Ser Cya Cly serrt;;'\Trp Ala Phe Cly Ala Val Clu Ala Ile Ser 
~~~~~-~~GGA~~~~~=~~=T~CC~~=~CTC~=~~ 
120 I I no uo 
A11p AtCjl Thr Cya Ile Bia Thr Aan Cly Arg Val Aan Val Clu Val Ser Ala Clu Aep Leu Leu Thr Cya Cya Cly Ile Cln Cy1 Cly Aap 
~==~~~~~==~~CTC~~~=~~~CTT~~~CCT~~~=~ 
150 uo 170 
Cly Cy1 Asn Cly Cly Tyr Pro Ser Cly Ala Trp Ser Phe Trp Thr Lya Lya Cly Leu Val Ser Cly Cly Val Tyr Aan Ser Bh Val Cly 
US GCC TGT MT CGT CGC TAT CCC TCT CGA CCA TGC ACC TTC TCC A.CA AAA AAA GGC CTC GT!' TCA CGT CGA CTC TAC MT TCT CAT GTA CGC 
!BO 190 200 
Cya Leu Pro Tyr Thr Ile Pro Pro Cy1 Clu Bh Bh Val Aan Cly Ser Arg Pro Pro Cya Thr Cly Clu Cly Aap Thr Pro Ar9 Cya Aan 
535 TCC TTA CCA TAC ACC ATC CCT CCC TCC C>.C C\C CAT GTC A.AT GGC TCC CGT CCC CCA TGC ACT CCA CAA CGA GAT ACT CCC AGG 'fCC MC 
210 220 230 
Lya Ser Cya Clu Ala Cly Tyr Ser Pro Su Tyt Ly1 Clu Aap Lya Bia Phe Cly Tyr Thr Ser Tyr Ser Val Ser Aan Sir Val Lya Clu 
625 A.AC ACC TGT CA>. CCT CGC TAC TCC CCA TCC TAC MA CAC CAT A.AC CAC TTT CGG TAC ACT TCC TAC ACC CTG TCT MC AGT GTC A.AG CAC 
2.tO 250 260 
Ile Met Ale Glu Ile Tyr Ly• A11n Gly Pro Val Glu Gly Ala Phe Thr Val Phe Ser A•p Phe Leu Thr Tyr Ly• Ser Gly Val Tyr Ly• 
715 ATC ATC GCA G>.A ATC TAC MA MT GGC CCA GTG GAG GCT GCC TTC ACT CTG TTT TCT GA.C TTC T'T'G ACT TAC MA TCA GGA GTA TAC AAG 
270 280 290 
Bis Cilu Ale Gly Alp Net Net Gly Cil~la Ile Arg Ile Leu Gly Trp Gly Val Glu Aln Gly Val Pro Tyr Trp Leu Ala Ala A•n 
805 CAT G>.A GCC GGT GAT ATC ATC GGT G~CC ATC CGC ATC CTG GGC TGG GGA. GTA GAG MT GG>. GTT CCC TAC TGG CTCi GCA GCC MC 
300 310 320 
Se-r Trp A1n Leu Asp Trp Gly A•p A1n Gly Phe Phe Lya Ile Leu Arg Gly Glu Aan 811 Cy1 Gly Ile Glu Ser Glu Ile Val Ala Cily 
895 TCT TCG MC C'M' GAC 'TGG GGT GA.T MT GGC TTC TTT MA ATC CTC AGA GGA G>.A MC CAC 1'CT GGC ATT ~ TCA GA.A ATT CTG GCT GGA. 
330 1 339 
Ile Pro Arg Thr A1p Gln Tyr Trp Gly Arg Phe OC 
985 ATC CCA CGC ACT GAC CAG TAC TGG GGA AGA TTC TA.A TCTGCTTTGAC"M'CATTGTCCA.GTCCM'AGGGCCTT'M"TCCA.AMTTTAGCGGCCCTGCCAGGG>.ATCAGGT 
1 09 2 AGACAGGGGA.GTC'Tr'TGATTCM'TGAGTTCA.TC'T A.ACATGCATGA.A.GC'TT'TTGGCAAGA.TTTGGACGACTGGACCAGAGCTGCCTGCCATCAGAGCTACCCTCCAM.CAC'TGTCCM'ACC 
1212 TCGCCTCC'TCCT ACCCCATCCCACGACAGTGATCACAGTCTGCATCCT AGCC'TCTCCC'T ACAC'T AGTGCGG'M'TCA.AGTGCCTGCTC"M"CTGGCTCTGCTGCCATACCTCCCACCCCCAT 
13 3 2 CCCCA.TCCCAGCA TCCGAGGACCCAAGGGC'TT'TGACTGCAGGACM'CCAAAAG>.ACGAACATTCACGAGAGGA.CMA TGCCACCTCTCAGCTGCA.TCTTGAAGCTGGTACM'CTGGGCTT 
14 5 2 GTGGCAGGCATTCGTCA.ATCGCCCAGTGCAGTTCTCTGGAGAA.AGCTACC'TTTTCCCAAGGCA'rCTGCATCCATCGACAT'T'GGTA.ATCTGGCCAGC'TC'TCC'TTCGTCCTGTCCTCAGCCG 
15 7 2 ATGCT'TTM'CA.ATAGGAi-rrTTATGCTr'TGTGT ACCTCAACCAAGTAT~GAGCTGTACTCCTTTTAT AGACTCACCCCCAATTCTA'TGGC"n'AAMCAAGCTACATCCTCATCGTTTC 
16 9 2 C'TGTGTGACCGACAGATMCCACAATCMAC'T AGTCTGG.V..V.AA.V.ACTC 111 t IGTTGT AGTT ACCACM' A.ACCCTCT AG'M'TAACAAGG>.ATGTC'TCTGC~CA.ATTCT 
la 12 CCC'TCTGC'M'~~T~~c AGGGCGGCAACGGTTCTGTGCTGCAGTTTCAAGGCTTTTCTCTCTCGCCCTGGTTTCCTCTCACCCTCAGMATCGTTCTCAM.CCCTACCTCTAACTGC'T 
19 J 2 CACACC'TCGGAGCAC'?"TCC'TCCTGCTT AGAGA T.v.GGGAGC'T ACACTTG1Tr A.ATTA.ACCMGGCGGGCAC'TC ACATACATATCACCCGGACT'GCCATCTTCTT AGAGGTCATTTCCTGG 
2 0 5 2 AGTCGGGGCCA.AAGC'M'GCGCACCATGTTT A.AGTTTTCTGGGTTACTCGATT'TCA TCGA'TTTT ACCA.AAM.TCATAGTGAAGTACAGTTCA.AAGGG>.ACACGGAGCCTCACTCA TC AGCG 
2172 TTGTCC'T ATGGATCTGTTACTTCCTGCTMGTCAGAGGGAGGGGCTGCTTTC'TCTGG>.AGCCCGCCTTCCCATGTCGGCA.ATCAGMC'TAT ATCAAAGA.AGCTCTGG>.TGCC'TGGCGAGT 
2 2 9 2 GCTAGAAGTGT AA CT CG CT1'TGAGGCAACCTCGC'TTCGGT ACTGGGGC'TT'T AGT ACTGCA.AGACAGTTCCACCGGTCTCA.ACTACGCCCA.AT AGTTCCCTCC'TACGCTTCC'M"TCTTGCC 
2 4 12 TC ACCACATGCCCACCTGCMC'TCCCTCCC'TACC'TCGCAT At;CCAGTCMGATCAGC'TMATTMGAGMGAGGACCC'TGA.ACATCC'TCTGATCGA.GCCCA.GGMACCCGTTT?'GTTATC 
2 53 2 GTATGCTTCGGGGTAC'TCTAGATGTCTTCCATAACCAGATTCTCC'TGT'TGGTCCCTTTCCTGTGCTCAAGTCA.AGAGCTCTC'?"TCCTTGGTACATGMA'TGGATACTCAGGAGACAGAGG 
26 52 CAAGCCAG'T'CTCTGGGAGT'M'GAGGCCAGACTGGTCTACA.ATAGACCTTGf'Jt,,GC'TAGGAGCATTTCC'TTTTCAGCCTGCCA.CAGGGCC'TTTTGATCATTC'TCTGTTTACACATCCC'TACC 
2772 i-rTCTACACAT'TAGAC'TAGA.ACACGCCGTTGTGTGTTC'M'TGTGTGGTCCTCA.AACCTGAGCCAGTATGAGTGCCACGCCTr'TGA.ATAGTCGTTTGTAGCCCGA.CTAGG'!'CAi-rTCAGAT 
2892 AGATT'TGGGCGATGGCC'M'CAA.ACAt;GGCCTATCACAGACAGCATTCATGCTGCCCA.GG>.ACTCATT.\GGTA.ACATGCCAGATCA.ACT'TGCTCAGA.AGTCTTGTrCCAGATCCATTAGA.A 
3 O 1 2 T ACAG>.ACT ACCC'M' AGCGCTCTCACTTCCACT ACCAC AGAGCCTCGGMACTCA.ACAGC AGGGGGA.ACGCCM'CA.AAGCGCTCTCCCAGACACGA.T'TTCCAM.TA.ACCAGAGGAACGT A 
31 3 2 GCMGCAC ,.,_ TCTT'T'CT AATM'M' ATCTCTCAT ATGGGTGGGCCTCTGAGA.AGC ACAC AGATCGTGT MATT AT A TTCAGAG'!'CA.A.v.GCAGGCC'T AGGGA.TCTCTCCATCCT AGAGTGTT 
3 2 5 2 TGTCCAGCATATTGTCCAAGCCA.AGACCCTTCGTTCCAGTGCCCACCCMCCACCM TA.Ji.CC AGGAGA.AAGACGTGTGTCA TATGTAGACAGTATGTATM TCTC CGA.CTAAA TGTA TTT 
r~!'OIJ'A 
3372 C'TAGATMTGGCTT'T'ATAGMATGCACCATCC'TMATAT'CT~A.AA.AC'TA'T'CTC:A.AATTCA.AGTCGA.AC'TTGGGGTC'TTA'l"M'GCTl'Jt,,GGGMATA.ACTM'CAGGGGC"CTAG 
3492 AGTCTGTC'CCCCC'TACCCC'TT'TATATTTA'M'CATGCAGTTTATGAGTACTCTGTCM'CA.TGCACATCAGA.AGGA.ATCGGATCTC'TAT'TATAG>.TCGTAGTGAGCCAC'TATGCCGTTCCTG 
)612 GGAATTGMCTTAGG>.CC'TCT'GG>.AGAACAC'TCAGGTGCTGAGCCATCTCTCCAGCC'TCCAGGT'M'TGA'l'G'M'AGAGACAGTCTCTTATGTAGTCCAGGCCCACCTCCA.CA.ACTGAGG>.G 
3 7 J 2 GATC'i'T MA.A TCCAACTCCTCCC'TTCC'TCCA TCCCCTCCCTCCACCTCCCACATGCTGGGA.TTACTCGT AAGAGTTGT AGCTTCCAG>.AAGGA.TG>..,t.. (.,1. '!"'! MACTTCGGT'M'CAGCGGG 
JS 52 GTCGGTA'M"T'CT'TCMGGCTTAGAGCAAt;TGACCAATGA.AGTCTCCATCCCCCAGTMTCCAGCA.AGGMT'CTGTCCTTAC~MTGG>.CCAC'TGMCTGGCCGAGGCACCTCAG 
3972 TG>.TGA.AG'TCA.ACATACGCAGC.\GGCTTAAGAGGGGAGCAGA.C'TATGC'!'CT'ACATGTC'TCTGTCGTCTGAGCGTACCCA.AAGGGTCATATACAGGTTCACAAAATGA.CACGTAGCTGACG 
4 0 9 2 CAC'TGT'TCTCAMAGGCTC AA TGC'T AGTCTTC CAGAGTT ACGGC'TCCAGAGACCMGCTCTGTGGA.CA.ACAGTGGCGTGGC'TCGTGCC'T AT MCTCGT ACA TTCAGA.AGGCTCAGGCAGT 
4 21 2 GGGATCAC CA '?'TA.AA T'TCA AGGCT ACAT AG>.C'i'TGC AGGCCAACCTGAGCTACAGTTACAGTGTACAAGTGTCAGCATGCCAGGGCGTCGACTCC'TGC"M'CCTG'TCACGTGCTCTCTC CT 
4 3 3 2 GC ATGTCCTCTC'T'CT ACTGT AGTCTCA 'M'T"C'?'CAC AAGGCCGTCCA.AGGGC'T AAA.GA TGGGGCCCCCCTC A TC'TTGT ACTTTCATCC'TCCT A.AGCi'GTT ACATMACA.ATCC'TC'TTTCC'T 
44 52 'T'GGTAAAGCAG'TTCGCCTCAGGTATCTTGTCC'TACCACGTCAAGAGTCGTTGCC'TAGAGCCTCTCCACCGCTCAACATCGT:'TCAG>.TACACACGGTGTCAGAt;GCCA.CCATGA.CA.ATGT 
4572 ,.,_GCCAACTAACCACGCTGCi'.AT'TAA.llfv.ccrAcCAATATAG - poly A 
Table 8. Difference in Cathepsin B cDNA sequences derived 
from Murine Bl6a Melanoma and Macophages 
Bl6a Melanoma 
Gly-143, GGT 
Ser-160, AGC 
Asn-174, AAT 
Val-177, GTA 
Pro-181, CCA 
Pro-197, CCA 
Cyo-198, TGC 
Gly-200, GGA 
Glu-201, GAA 
Gly-202, GGA 
Pro-205, CCC 
Gly-276, GGG 
Macrophages 
(Chan et al,1986) 
Gly-143, GGC 
Asn-160, AAC 
Asp-174, GAT 
Ile-177, ATA 
Pro-181, CCG 
Pro-197, CCG 
Cyo-198, TGT 
Gly-200, GGG 
Glu-201, GAG 
Gly-202, GGG 
Pro-205, CCA 
Gly-276, GGT 
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Restriction Maps and Sequences of Melanoma Cathepsin B cDNAs. 
Five representative cathepsin B cDNA clones were mapped 
with restriction enzymes and sequenced as shown in Figure 21. 
Among these, two (A.mB16a5'-CB6 and AmB16aG4) were isolated 
with the 1.2 kb preprocathepsin B cDNA probe, two (~mB16aCB5 
and ~mB16aCB1) were isolated using the 3' downstream region 
of the gene, BH3.8 probe and one (pmB16aCB19) was obtained 
using a PCR approach as described in Chapter III (Materails 
and Methods). The cDNAs overlap as shown in Figure 21 and the 
three clones, A.mB16aG4, /\.mB16aCB5 and 1\mB16aCB1, each has a 
poly(A) tail over 100 nt in length. However, the adjacent 5' 
sequences are different, indicating that alternative 
polyadenylation sites are used. The deduced coding sequence 
for preprocathepsin B from melanoma clones (Figure 22) was 
nearly identical to that of mouse macrophage-derived 
preprocathepsin B cDNA presented by Chan et al (1986), except 
for the differences noted in Table 8. These nucleotide 
changes may have been sequencing artifacts in earlier work 
since I resequenced the macrophage-derived cathepsin B cDNA 
and found the sequence to be identical to the melanoma-derived 
cathepsin B cDNA sequence. 
Sequence analysis of the 3' downstream regions 
corresponding to the two large transcripts in clones J\.mB16aCB5 
and i\lnB16aCBl (Figure 21) failed to detect any contiguous open 
reading frame beyond the carboxyl terminus of cathepsin B at 
residue 339. From the results shown in Figures 21 and 22 it 
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can be determined that the 2.2, 4.0 and 5.0 kb transcripts 
differe only in the length of their 3 1 untranslated regions. 
Moreover, the 3' untranslated sequences of the melanoma-
derived preprocathepsin B cDNA were identical and contiguous 
with the 3' downstream sequence of the cloned mouse cathepsin 
B gene, thus proving that they were transcribed from a 
continuous region of the cathepsin B gene and did not arise 
via alternative splicing. The canonical AATAAA 
polyadenylation signal was found in the 2. 2 kb transcript 
located 18 nucleotides upstream from the poly(A) tail. 
Variants of the polyadenylation signal, TATAAA and AATTAA, 
were observed 12 and 14 nucleotides upstream from the poly(A) 
sequences in the 4.0 and 5.0 kb transcripts, respectively. 
Mapping the 5 1 End of Cathepsin B mRNAs in normal tissue and 
B16a melanoma. 
The above data demonstrated that the three cathepsin B 
RNA transcripts found in the B16 melanoma contained 
alternative 3 1 untranslated regions. To determine whether 
these transcripts have the same or different transcription 
start sites, an RNA protection assay was performed. Figure 
23 shows that both B16a Melanoma and murine kidney RNA 
protected the same size fragment from nuclease digestion and 
no additional protected fragment is detectable for B16a 
melanoma compared to kidney. These results indicate that all 
three cathepsin B mRNA transcripts in B16a melanoma have the 
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same transcription start site, which is also identical to that 
for normal tissue derived cathepsin B m.RNA. The major 
protected fragment extends 133 nucleotides upstream from the 
translational initiation codon for mouse preprocathepsin B. 
Failure to Detect the large Transcripts of Cathepsin B in 
Mouse Normal Tissues 
A cDNA fragment (Hind III and Bgl II fragment in 
mB16aCBl in Fig. 21) unique to the 4.0 and 5.0 kb cathepsin 
B m.RNAs was used as a probe to determine whether small amounts 
of the larger sized transcripts also occur in normal murine 
tissues including kidney, which is the normal murine tissue 
with the highest level of cathepsin B m.RNA, liver and spleen. 
Autoradiography failed to reveal the presence of larger sized 
cathepsin B m.RNA transcripts in any of these normal tissues 
even with loading large amount of mornal tissue RNA (up to 60 
µg/well) and prolonged exposure of the filter to X-ray film 
(Figure 24). This result agrees with our earlier failure to 
detect 4.0 and 5.0 kb cathepsin B mRNAs in normal tissues from 
mice using the 1.2 kb cathepsin B cDNA probe. 
Figure 23. Mapping 5' Ends of cathepsin B mRNAs 
in Kidney and Bl6a Melanoma 
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In vitro synthesized 32 P-cRNA corresponding to the 5 1 end 
of the mouse cathepsin B gene was hybridized with 40 µg of 
either total mouse kidney RNA (Lane 1) or Bl6a melanoma RNA 
(Lane 2) and digested with RNase A and RNase Tl. The 
protected fragments were analyzed on a 8% polyacrylamide/8 M 
urea gel. The sequence ladder in lanes G, A, T and c was 
obtained by using a primer which has the same 5'-end as that 
of the protected cRNA with cloned 5 1 -end mouse cathepsin B 
gene as template. The arrow indicates the major protected 
fragments for Bl6a melanoma and mouse kidney. 
Figure 23. Mapping 5' Ends of Cathepsin B m.RNAs 
in Kidney and Bl6a Melanoma 
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Figure 24. RNA Blot hybridization Analysis with Two Diffrent 
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Total RNAs from mouse kidney (lane 1, 30 µg), liver (lane 
2, 60 µg), B16a melanoma (lane 3, 10 Ig) and spleen (lane 4, 
30 Ig) were denatured, separated by electrophoresis through 
a 1.2% agarose gel and transferred onto nitrocellulose. Panel 
A: Blot was hybridized with a 1.6 kb Hind III-Bgl II fragment 
isolated fromAmB16aCB1 (Figure 21). Panel B: Duplicate blot 
was hybridized with mouse preprocathepsin B cDNA (Chan et al, 
1986). Sizes of RNA ladder molecular markers (BRL) are 
indicated by the numbers on the left margin. 
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Cloning of the Mouse Cathepsin B Gene 
Two clones- ~mEGB2 and .NnGBS (Fig. 25) were identified 
by screening with mouse cathepsin B cDNA probes. These two 
clones encode exon 1 through part of exon 7 and part of intron 
8 through exon 10, respectively. The rest part of the gene, 
including the missing portions of exon 7 and intron 8, entire 
intron 7 and exon 8, was isolated by PCR as described in the 
Chapter III, the resulting two clones are shown in Fig. 25 as 
pmGB550 and pmGB700. 
The 5'-end of mouse cathepsin B cDNA was cloned using 
RACE method. The sequence of one of these clones is shown in 
Fig. 26a. This clone was used as a probe to identify exon 1. 
Transcriptional Start Site and Seguence of 5'-Flanking Region 
The nucleotide sequence adjacent to exon 1 is shown in 
Figure 27. Both RNA protection (Fig. 26c) and primer 
extension (Fig. 26b) assays generate a major band, indicating 
the putative principle transcription starting site is 133 
nucleotides upstream from the translational start site and 
eight nucleotides upstream from the 5 1 -end of the RACE 
product. The observation of several minor bands in the assays 
suggests the presence of minor transcription sites. There are 
three potential Spl binding sites in the 5 1 flanking region. 
However, there are no TATA and CAAT motifs within 100 nt 
upstream from the principle transcription start site (Fig. 
27). The exon 1 and 5' flanking region is very GC rich. 
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Figure 25. Restriction Map and Schematic Structure of Mouse 
Cathepsin B Gene 
Exon 1 2 3 4 5 6 7 8 9 10 
~ ~ 11 I II I I~ 
H3 H3 H H RI 
L---'---'-'---'---'-----~-~---~ /\ mEGB2 
RI RI 
LJ pmGB750 
u pmGB500 
H3 RI H3 H3 
»mGBB 
1kb 
L____J 
The exons are indicated by both hatched line boxes (5'-
and 3'-end non-coding regions) and solid boxes (coding 
region) . The three parts of the last hatched box indicate the 
three potential transcription regions. The names of each 
clones are noted. Restriction sites are indicated: RI (Eco 
RI), H3 (Hind III). 
102 
Figure 26. Identification of the Transcription Initiation 
Site of Mouse Cathepsin B Gene 
a: Sequence of the 5' -end of cDNA. The clone was 
obtained with RACE procedure. When compared to the results 
of primer extension and RNA protection assays, it can be seen 
that 5 1 -end of the cDNA is only 8 nucleotides away from the 
principle transcription start site. 
b: Primer Extension. 5 µg of mouse kidney total RNA and 
1 pmol of the 32P-abeled oligonucleotide complementary to 
nucleotides 48 to 65 of the m.RNA were hybridized and extended 
with AMV reverse transcriptase. The primer-extended products 
were separated on a 8% polyacrylamide/8 M urea gel. The 
right-hand lane shows the primer-extended cDNA. The sequence 
ladder was obtained by using the same oligonucleotide as a DNA 
sequencing primer on a 5' upstream fragment of the mouse 
cathepsin B gene as a template. 
c: RNA Protection. A radioactive antisense RNA probe 
corresponding to a 5'-end fragment of the mouse cathepsin gene 
was hybridized with mouse kidney total RNA and digested with 
RNase A and RNase Tl. The reaction was analyzed on a 8% 
polyacrylamide/8 M urea gel. The left-hand lane shows the 
protected fragment. The sequence ladder was obtained by using 
an primer which has the same 5 '-end as that of 32P-labeled cRNA 
and a template which is the 5 1 upstream fragment of the mouse 
cathepsin B gene. 
The arrows indicate the major transcription start site. 
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Figure 26. Identification of the Transcription Initiation 
Site of Mouse cathepsin B Gene 
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Figure 27. Nucleotide Sequences adjacent the 1st Exon 
TTGGTAAGTAAGAGCTCTACTTCTGGGCTACAATCCCAGCCCAGTTCTAG 
TTTTTGGTTGCTTCCCTTGGTTTGAGTATTTCTACGCCATTATAGTCTGA 
GCTTCAGAATATAAGGCCAGGAGGCTCCTCCAGACATTTCCAGGTCCCGA 
GCCAGCGGGGCCTTCCCGAGGAATGCATGTCACGAAGATGTTGTATCTTC 
CCAGTGCAGGGTACCTGCAGAGGTCCCTGGAGAGCATCTCTGTGCGAAAT 
GGAAAGAGAGCAGACAAACCACCAGTTTCTTTTGGGTTTAACACAGCTTG 
CAGAGTCCCGGGATGAAGGGGGAGGGGCCGGCAGGGGCGGGGGCGCGGTC 
1 
AAGCATCACGTGACGAATC CCCCCAGCGGAGGGCGGACGGCGCGGGTA 
CTTAGGAGTGCACGGGAGAGGCCAGGAGCGGCTCCGTTTGGCTTGGTGGC 
TGCAGGCCCAGGCTGTCGCGCTGCGCTCGGTG TTTGCCCGGGGACAGT 
GGCTCCATGGCGGAAGTCACTTTGGCTGGGGTCGGGGGAGCGGGCTGAGC 
ACCGGTGGTGGAGACA 
Exon 1 is boxed. 1 indicates putative transcription 
start site. Arrowhead indicates the end of cDNA obtained by 
RACE method. The regions representing potential binding sites 
for the transcriptional factor Spl are underlined. 
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_IDCon-Intron Organization of Mouse cathepsin B Gene 
The ten exons of the mouse cathepsin B gene span about 
20 kb. The exon sizes are all about 100 bp long (from 86 to 
147 bp) except for exon 10. The intron sizes vary strikingly 
ranging from 150 bp to about 4, 750 bp. The boundary sequences 
of the exon-intron junctions conform to the GT ... AG rule 
(Breathnach and Chambon, 1981). 
Exon 1 encodes most of 5 1 -untranslated region of the 
mRNA, exon 2 encodes additional 30 nucleotides of the 5 1 -UTR 
(untranslated region) , the entire 17 amino acid signal peptide 
and the first 25 amino acids (aa18-42) of the 62 amino acid 
propeptide. Exon 3 encodes 29 amino acids (aa43-71) in the 
propeptide. Exon 4 encodes the remaining 8 amino acids (aa72-
79) of the propeptide and the first 30 amino acids (aaS0-109) 
of the mature enzyme. Exons 4-10 encode most of the mature 
protein (aall0-307). Exon 10 is the largest exon but encodes 
only 32 amino acids (aa308-339) of the mature protein followed 
by the translation stop codon and the entire 3 1 -untranslated 
sequence. In comparing exon 10 to cathepsin B cDNA sequences 
cloned from the mouse B16a melanoma, it is evident that the 
three polyadenylation sites, which are alternatively used in 
transcription of the cathepsin B mRNAs in the B16 melanoma, 
are all located in this exon. Thus, the size of exon 10 is 
either 901, 2,512 or 3,691 bp depending on which 
polyadenylation site is used. Table 9 shows the summary of 
the gene organization. 
Table 9. Exon-Intron Organization of Mouse cathepsin B Gene 
Exon In tr on 
Exon size 
No. hp 
1 112 
2 147 
3 86 
4 115 
5 119 
6 86 
7 144 
8 117 
9 129 
10 901 
2,512 
3,691 
Sequence at intron-exon junction 
3' splice acceptor 5' splice donor 
--GGTGAgtttgcccgg----
----tcctttctagGTGAG-------GGCAGgtaggcacgc----
----gctctttcagGCTGG-------GGAAGgtgagtgaca----
-- -ttttgcctagGGTTG-------GTTGGgtagacctct----
-- -attaccgcagGCATT-------GACGGgtgagtgttg----
----tctttttcagCTGTA-------TGTAGgtgagtgtgt----
- --catctgtcagGCTGC-------CTl'TGgtaagctggg----
- --ctttttacagGGTAC-------ATCAGgtaccagtca----
----gacaaatcagGAGTA-------TAATGgtgagtggca----
----cccatcccagGCTTC--
size 
hp 
-4750 
234 
750 
Amino acid 
interrupted 
CAG GCT 
Glu-42-Ala-43 
AGG 
Arg-71 
TGG GCA 
Trp-109-Ala-110 
GGC 
Gly-149 
GGC 
Gly-178 
GGG 
Gly-226 
GGA 
Gly-265 
GGC 
Gly-308 
...... 
0 
O'\ 
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s_outhern Blot Analysis of cathepsin B Gene in Murine Liver and 
a16a Melanoma 
The genomic DNA extracted from both tissues were digested 
with Eco RI, Bam HI and both enzymes, respectively. The blot 
was hybridized with labeled mouse cathepsin B cDNA. As the 
souther blot results showed in Figure 28, there is no 
difference observed in either the patterns or the densities 
of the DNA bands between normal liver and Bl6a melanoma. This 
result suggests that: (1) there is no gross chromosome 
rearrangement; (2) there is no amplification of cathepsin B 
gene in Bl6a melanoma. 
Half Life of Cathepsin B mRNA 
After cells were treated with Actinomycin D for various 
time, both RNA dot blot (Fig. 29) and Northern blot (Fig. 30) 
analyses were performed to measure half life of cathepsin B 
mRNA in NIH3T3 fibroblasts, Bl6a and Bl6Fl cells. The 
calculated half-life of cathepsin B mRNA was -6 hours for 
NIH3T3 fibroblast, -25 hours for Bl6Fl and -30 hours for Bl6a 
melanoma cells. It is clear that half life of cathepsin B 
mRNA in Bl6a melanoma cells is longer than that in B16Fl, and 
much longer than that in the fibroblasts (Fig. 30). 
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Figure 28. Southern Blot of Genomic DNA From Normal Murine 
Liver and Bl6a Melanoma 
The numbers on the left side indicate molecular weights 
in base pairs. RI refers to Eco RI. Barn refers to Barn HI. 
20 µg digested DNA was loaded in each well. Hybridization was 
performed withlabeled mouse cathepsin B cDNA insert. 
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Figure 28. Southern Blot of Genomic DNA From Normal Murine 
Liver and B16a Melanoma 
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Figure 29. RNA Dot Blot Hybridization Analysis for 
Measurement of Half Life of Cathepsin B mRNA 
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Total RNAs were extracted from mouse B16a, B16Fl melanoma 
cells and NIH3T3 fibroblasts which were treated with 
actinomycin D (5 µ/ml) for indicated time. For each time 
point four flask cells were used. The RNAs were denatured and 
spotted onto nitrocellulose. The blots were hybridized with 
32P-labeled mouse cathepsin B cDNA and autoradiographed. 
Figure 29. RNA Dot Blot Hybridization Analysis for 
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Figure 30. RNA Blot Hybridization Analysis of Mouse Bl6a 
Melanoma Total RNA 
The Bl6a melanoma cells were treated with actinomycin D 
(5 µg/ml) for various length of time from o to 12 hours as 
indicated in each lane. Four dishes were used for each time 
point. The RNAs extracted from the cells were denatured and 
separated by electrophoresis through 1.2 % agarose gel. The 
blot was hybridized with 32P-labeled mouse cathepsin B cDNA. 
Arrows indicate cathepsin B mRNA bands with the sizes of 5 kb, 
4 kb and 2.2 kb, respectively, from top to bottom. 
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Figure 30. RNA Blot Hybridization Analysis of Mouse B16a 
Melanoma Total RNA 
0 3 5 7 12 
Figure 31. Half-Life of cathepsin B mRNA in NIH3T3 
Fibroblasts, Bl6a and Bl6Fl Melanoma Cells 
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Half-life was measured using RNA dot blot results (Figure 
29). The autoradiographies were subjected to densitometer 
scanning analysis. Relative dot intensity readings were 
plotted as a function of the time of transcription inhibition 
by actinomycin D. Each time point in the panels was the 
average of two separated experiments. mRNA half-lives were 
determined by a least-squares linear regression calculation 
of the plotted data. 
Figure 31. Halfe-Life Of Cathepsin B mRNA in NIH3T3 
Fibroblasts, B16a and B16Fl Melanoma Cells 
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CHAPTER V 
DISCUSSION 
CHARACTERISTICS OF RAT CATHEPSIN H 
In order to investigate the expression of the five 
cathepsins in normal tissues and in malignant tumors, it was 
necessary to first clone cathepsin H, which is an important 
member in the cathepsin family and the only cathepsin which 
had not been cloned at the time when I started this research. 
The successful cloning of rat cathepsin H cDNA provided not 
only a cDNA probe, but also better understanding of this 
enzyme. 
While cathepsin B and L are well characterized, much less 
was known about cathepsin H, especially at the molecular 
level. cathepsin H was originally isolated from rat liver 
(Kirschke et al, 1976), as an approximate 50:50 mixture of a 
single chain and a two chain form. Both forms are 
glycosylated and the conversion of the single chain form to 
the two chain form involves a limited proteolytic cleavage 
near the carboxyl terminus. The complete amino acid sequence 
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of the mature enzyme was published in 1983. It contains a 
total of 220 amino acids (Takio et al, 1983) with a site for 
glycosyl attachment. The amino acid sequence deduced from the 
sequence of cloned cDNA indicates that the mature form of 
cathepsin H is formed from a precursor by limited proteolysis, 
and that the propeptide additionally contains two putative 
glycosylation sites. These could play an important role in 
intracellular protein sorting. The cDNA derived sequence 
predicts that the two chain form is generated directly by 
cleavage between residues 177 and 178 without the loss of any 
intervening residues, which contrasts with cathepsin B where 
cleavage results in the loss of a dipeptide (San Segundo et 
al, 1985). Again, unlike cathepsin B, limited proteolytic 
modification of the c-terminus of cathepsin H does not occur. 
The deduced amino acid sequence of the mature enzyme coincides 
completely with that determined by the protein sequencing 
method. Ishidoh and co-workers (1987) independently cloned 
rat cathepsin H cDNA almost the same time as I did. My 
sequence agrees with theirs except for three nucleotides in 
the 3 1 -untranslated region. Whether this difference reflects 
a polymorphism or sequence artifacts remains to be 
established. 
Northern blot analysis of total RNA from ten rat tissues 
demonstrated the presence of a single, 1. 6 kb cathepsin H 
mRNA. Quantitative study by RNA dot blot disclosed a greater 
than 50 fold variation in cathepsin H mRNA level between 
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different tissues. The highest level is observed in kidney 
while the lowest level is in pancreas. Substantial amounts 
were also observed in lung, liver, uterus and spleen. In 
contrast, pancreas, thymus and brain have relatively low 
concentration of cathepsin H mRNA. 
CHARACTERISTICS OF EXPRESSION OF FIVE CATHEPSINS IN NORMAL RAT 
AND MOUSE TISSUES 
Although four 
proteinases which 
of the five cathepsins are cysteine 
share some degree of structural and 
functional homology, no cross-hybridization was observed among 
the cathepsin cDNAs under the high stringency condition 
employed in my studies of the expression of five cathepsins 
in various of tissues. This permitted accurate measurements 
of relative mRNA levels in different tissues for all five 
cathepsins. The distribution of five cathepsins shows that 
they have certain common features: lung has very high levels 
of mRNAs for all five cathepsins, 
lowest mRNA levels for all of them. 
while pancreas has the 
Kidney has the highest 
levels of mRNA for cathepsin B, H and L, and intermediate 
level of cathepsin D mRNA. This is generally in agreement 
with the reports on the distribution of cathepsin B, H 
(Kominamal et al, 1985), L (Bando et al, 1986) and D (Whitaker 
and Rhodes, 1983) in rat tissues by immunochemical assays. 
On the other hand, the mRNA levels for the five enzymes were 
distributed in a non-parallel fashion among many of the normal 
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rat tissues. For example, heart contains significant levels 
of cathepsin B, D and L but low levels of cathepsin H and S; 
spleen has high levels of cathepsin s, intermediate level of 
cathepsin B, D and H whereas low level of cathepsin L. The 
uneven distribution is also reflected by the fact that there 
is a 50-fold difference in the cathepsin H mRNA level, 25-fold 
difference in cathepsin s mRNA level and about 10-fold 
difference in cathepsin B, D and H mRNA levels across 
different tissues. 
The broad tissue distribution of the five cathepsins 
agrees with the hypothesis that cathepsins play an important 
function in intracellular protein degradation. The high level 
of cathepsins in kidney is entirely consistent with its role 
in the clearance and degradation of small proteins {Kim et al, 
1989; Maack et al, 1979). The ability of alveolar macrophages 
to degrade abnormal or foreign proteins may similarly account 
for the presence of high levels of cathepsins in the lung. 
Similarly, the low levels of cathepsins in the pancreas agree 
with the finding that this tissue does not contribute 
significantly to the degradation of circulating plasma 
proteins {Carew et al, 1982). Most striking is the uneven 
distribution of cathepsin mRNAs among most of the tissues 
studied, indicating that their expressions are individually 
regulated. Consequently, one would expect from such results 
that the proteolytic enzyme composition of lysosomes varies 
from organ to organ, presumably reflecting the specialized 
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physiologies and underlying functional differences between 
tissues (San Segundo et al, 1986) . However, how the lysosomal 
proteinase content reflects function is not clear, 
particularly as the roles of individual lysosomal proteinases 
in protein catabolism and cellular function in vivo are 
essentially unknown. 
ENHANCED EXPRESSION OF CATHEPSIN B IN RAT W-256 CARCINOSARCOMA 
AND IN MOUSE B16 MELANOMAS 
A great many reports have indicated elevated cathepsin 
B (Keren and LeGrue, 1988), D (Maguchi et al, 1988, 
Maudelonde, 1988) and L (Gal and Gottesman, 1986, Treen et al, 
1988) or cathepsin B-like enzymes (Dufek et al, 1984) in 
different tumor cells. Indeed, elevated proteinase expression 
has been thought to be a marker of the tumorigenic and/or 
malignant state (Koppel et al, 1984; Sloane et al, 1981) . 
Most of these experiments used enzymatic or immunochemical 
methods to detect and quanti tate these enzymes. However, 
using activity measurements to estimate enzyme levels suffer 
from severe uncertainties concerning the specificity of the 
substrates. Immunochemical methods may be compromised by 
differences in the immunoreactivities of precursor and mature 
forms of the lysosomal enzymes and by the cross-reactivity 
between closely related cysteine proteinases (Wiederanders and 
Kirschke, 1986). Consequently, I have employed the cDNAs for 
five cathepsins to examine their expression in a Walker rat 
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carcinoma (LLC-WRC 256) and mouse B16 melanomas. I have 
proven that the DNA probes used in this method is very 
specific for each cathepsin under high stringency condition. 
The key word here is "high". cross reaction among different 
cathepsins could occur if otherwise low stringency condition 
is used since the structures of cysteine cathepsins are 
closely related. 
The Walker-256 rat carcinosarcoma arose in a pregnant 
albino rat in 1928 in the laboratory of John Walker at Johns 
Hopkins University School of Medicine. Since then it has been 
one of the most frequently used tumors in cancer research 
(Rosenoer et al, 1966). Mouse B16 melanomas are a type of 
skin cancer which can have a high degree of malignancy. The 
three variants of B16 melanomas were developed from same 
origin and B16a, B16F10 and B16Fl have high, intermediate and 
low metastatic potentials (Filder, 1973; Qian et al, 1989). 
The measurement of the five cathepsin mRNA levels in 
Walker-256 carcinosarcoma and B16 melanomas gave consistent 
results, which revealed that mRNA levels for cathepsins D, H, 
L and s in these tumors all appeared to fall within the range 
observed for normal tissues. In contrast, the mRNA levels for 
cathepsin B in W-256 and B16a tumors are three fold higher 
than those seen in kidney and lung, the two tissues with the 
highest expression levels of cathepsin B among the ten normal 
tissues studied. Considering melanoma is a skin cancer, if 
we use skin as control B16a is 10 fold, B16F10 is 2.5 fold and 
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Bl6Fl is 1. 5 fold as high as mouse skin as a result of 
comparison of their cathepsin B levels. However, a more 
appropriate control would have been melanocytes if they were 
available. 
These results confirmed the reports of enhanced 
cathepsin B activities observed in a variety of tumors such 
as murine fibrosarcomas (Keren and LeGrue, 1988), human liver 
cancer (Dufek et al, 1984), human ovarian carcinoma (Mort et 
al, 1981), human genital tract cancer (Pietras and Roberts, 
1981) , rat pancreatic carcinoma (Koppel et al, 1984) , and 
human (Petrova-Skalkova et al, 1987) and mouse breast 
carcinoma (Recklies et al, 1982). In addition, my present 
results are in agreement with the report for human colorectal 
adenocarcinoma (Kepper et al, 1988) , which indicated high 
levels of cathepsin B and cathepsin B-like proteinase while 
low levels of cathepsin H and L. The reason for a specific 
elevation of cathepsin B expression in these tumor cells 
remains to be established. 
CORRELATION BETWEEN CATHEPSIN B AND METASTATIC POTENTIAL 
The differences among the three melanoma variants are in 
their abilities to colonize in the lung following intravenous 
(tail vein) or subcutaneous injection. Assays of metastatic 
potential based on lung colonization after the intravenous 
injection indicated that Bl6-Fl0 is more metastatic than Bl6-
Fl. In contrast, study of metastasis from solid tumors 
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implanted at a subcutaneous site gave somewhat different 
results in which neither the Bl6-Fl or the Bl6-Fl0 melanoma 
cells produced significant numbers of secondary tumors. 
similar discrepancies between the two assays of metastatic 
potential have been observed previously (Gehlsen et al, 1986) 
and may be attributed to the fact that they measure different 
steps in the metastatic process. Thus, the subcutaneous assay 
measures detachment of cells from the primary subcutaneous 
tumor, invasion of the vasculature (intravasation), arrest in 
the capillaries in the lung (attachment), invasion through the 
capillary wall (extravasation), colonization and 
proliferation. The intravenous assay measures only 
attachment, extravasation, colonization and proliferation. 
However, in both assays of metastasis, the Bl6a cells showed 
a much higher metastatic activity than either the Bl6-Fl or 
Bl6-Fl0 cells. of the 5 cathepsins studied, only the mRNA 
level of cathepsin B was elevated in the Bl6a melanoma and the 
mRNA levels in the three melanoma variants correlated 
positively with their metastatic potential, especially when 
measured by subcutaneous injection assay. The ratio of lung 
colonies formed after subcutaneous injection of Bl6-Fl, Bl6-
Fl0 and Bl6a tumor cells was 1:1.5:30 and the corresponding 
ratio of cathepsin B mRNA levels in Bl6-Fl, Bl6-Fl0 and Bl6a 
was 1:1.5:7. Moreover, these relative mRNA levels also agree 
with the levels of latent cathepsin B secreted by the tumor 
variants (Qian et al, 1989). These results are consistent 
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with the enzymatic study by Sloane et al (1981) who found that 
there was a relationship between cathepsin B activity and 
metastatic potential of B16 melanomas. In contrast, level of 
cathepsin D and other hydrolytic enzymes showed no 
relationship with metastatic potential in these cells. The 
finding that cathepsin B mRNA and the secreted enzyme levels 
correlated well with metastatic potential based on the 
subcutaneous assay, but less well when based on the 
intravenous assay suggested that cathepsin B may have a role 
in cell detachment (Sylven, 1968) and/or intravasation. This 
could explain the inability of inhibitors of cathepsin B to 
block the metastasis of B16-F10 melanoma cells following 
intravenous injection (Ostrowski et al, 1986). This result 
is in agreement with the recent report by Sheahan et al (1989) 
who observed significantly higher cathepsin B activities in 
colorectal cancer patients with Dukes' A tumors (tumors 
confined to the bowel wall) than in patients with more 
advanced tumors (Duke' B, c, or D tumors) and suggested that 
cathepsin B may play an important role in the early 
progression of human colorectal carcinoma. 
ALTERNATIVE TERMINATION OF TRANSCRIPTION 
A significant new finding in this present work is the 
detection in all three B16 murine melanoma variants of two 
larger cathepsin B mRNA transcripts (4 kb and 5 kb) which were 
not detected in any of the normal tissues studied. Cloning 
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and sequencing results revealed that the 4. o and 5. o kb 
transcripts have unusually long 3 '-untranslated sequences. 
The alternative utilizations of polyadenylation signals 
explain the differences between the three cathepsin B mRNA 
transcripts (2.0, 4.0, 5.0 kb). 
The vast majority of mRNAs in eukaryotic cells are 
polyadenylated (poly A) at their 3 '-ends. Al though this 
modification was observed a number of years ago, the mechanism 
by which it occurs is only poorly understood. Early 
experiments (Nevins and Darnell, 1978) with adenovirus late 
transcription unit revealed approximately equal molar 
transcription proceeding and following polyadenylic acid 
addition sites, suggesting that a large pre-mRNA is 
specifically cleaved to create a 3' end which subsequently 
undergoes poly A addition. Similar studies with cellular 
genes yielded similar results (Hofer and Darnell, 1981). 
The nucleotide sequence 5'-AAUAAA-3 1 , or a closely 
related variant of it, has been found approximately 10 to 30 
nucleotides upstream of the 3 '-ends of all poly A mRNAs 
studied (Berget, 1984; Proudfoot and Brownlee, 1976). 
Deletion or point mutation in this signal prevents 
polyadenylation (Fitzgerald and Shenk, 1981, Higgs et al, 
1983). In addition,a sequence located downstream or 3'to the 
AAUAAA motif was identified by deletion analysis and shown to 
modulate the efficiency of polyadenylation (Simonsen et al, 
1983; Conway et al, 1985; McDevitt et al, 1984). However, 
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this sequence is less well conserved. 
Site-specific polyadenylation clearly requires more than 
poly(A) polymerase, since this enzyme, when purified, lacks 
sequence specificity (Edmonds and Winters, 1976). Other 
proteins have been identified to be involved in site-specific 
polyadenylation including nuclear RNP particles (Moore and 
Sharp, 1984 and 1985; Hashimoto and Steity, 1986), a 64 kd 
nuclear protein (Wilusz and Shenk, 1988) and a cleavage and 
adenylation factor, CAF (Christofori and Keller, 1988). 
There is now evidence that the selection of a poly (A) 
site can be a regulatory event controlling gene expression 
when multiple poly (A) sites exist within a single 
transcription unit. This possibility has been demonstrated 
in several case, such as the adenovirus late poly (A) sites 
(Nevins and Wilson, 1981), the immunoglobulin µ poly (A) sites 
(Mather et al, 1984; Yuan et al, 1984), and the calcitonin and 
CGRP poly (A) sites (Amara et al, 1984) • Each of these results 
suggests the presence of either tissue-specific factors 
(calcitonin/CGRP) or factors appearing during a developmental 
pathway (adenovirus and immunoglobulin) that are responsible 
for selective poly (A) site utilization. 
In the case of cathepsin B mRNAs, no mutation or deletion 
of the AATAAA sequence or modification in the downstream 
sequences of the AATAAA modify are detected in any of the 
transcripts. Clearly, the cause of multiple cathepsin B 
transcripts is not due to mutation or deletion. 
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Alternative utilization of polyadenylation sites 
resulting in divergent 3'-untranslated regions has been 
reported for other tumor mRNAs as well, such as the amylin 
mRNAs in a human insulinoma (Sanke et al, 1988) and .82-
macroglobulin mRNAs in a mouse teratocarcinoma (Parnes et al, 
1983) . However this observation is not limited to tumor 
cells. Multiple mRNA species with distinct 3' untranslated 
regions have been also found in transcription products in 
normal cells, including dihydrofolate reductase (DHFR) in 
mouse liver and cultured mouse cells (Setzer et al, 1980), B-
subunit of alcohol dehydrogenase in human liver (Heden et al, 
1986) and a-amylase in both mouse liver and salivary gland 
tissues (Tosi et al, 1981) . The mechanisms for such a 
phenomenon are unclear. In the present case, since the 
multiple cathepsin B mRNA transcripts were detected only in 
the melanomas but not in normal tissues, it is conceivable 
that the appearance of two novel transcripts is related to the 
development of the tumor. It is possible during the tumor 
development process, certain factor or factors appear, which 
alter the utilization of potential polyadenylation sites. A 
tumor-type poly(A) polymerase has previously been identified 
(Rose et al, 1976) and detected in the sera of rats bearing 
tumors and in some cancer patients, but absent in heal thy 
individuals, cancer patients in remission for several months 
and hypertensive patients or patients with certain 
inflammatory diseases (Stetler et al, 1981). The tumor-type 
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poly(A) polymerase is present even prior to the formation of 
preneoplastic nodules in the sera of rat fed with 
hepatocarcinogens (Stetler et al, 1984). Anti-tumor-type 
poly(A) antibodies can inhibit polyadenylation of Adenovirus 
L3 pre-mRNA and surprisingly, inhibit the cleavage reaction 
when it was coupled or uncoupled with polyadenylation (Terns 
et al, 1989; Jacob et al, 1989). It is possible the tumor-
type poly(A) polymerase in concert with other factor(s) play 
an role in the formation of additional cathepsin B mRNA 
transcripts in B16 melanomas. The detection of the tumor-type 
poly(A) polymerase and alternatively polyadenylated mRNAs 
together might be an unique tumor marker. Further studies are 
required to validate this possibility. 
Study of short lived mRNAs such as c-fos, c-myc and 
lymphokin mRNAs indicated a major determinant of the rapid 
turnover of these mRNAs is the multiple copies of AU-rich 
motifs (consensus sequence UAUUUAU) common to the 3 1 UTRs of 
these mRNAs (Caput et al, 1986; Wilson and Treisman, 1988; 
Jones and Cole, 1987). Transfer of these segments to the 
3 1 UTR of stable mRNA such as globin mRNA dramatically reduces 
its stability (Shaw et al, 1986). However, there is no any 
UAUUUAU motif in the 3!.UTRs of 2.2 and 4.0 kb transcripts and 
only one copy in the 3!..UTR of the 5.0 kb transcript. 
Other studies demonstrated Polyadenylation and 3 !.UTR have 
significant effects in translation efficiency. The addition 
of long poly (A) tail increased the rate of lysozyme mRNA 
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translation in oocytes by 20-fold and chymosin mRNA 
translation by 10-fold (Drummond et al, 1985). Sequences in 
the 3'UTR can also influence translation efficiency in vivo. 
The most striking case is that of the human a-interferon (IFN) 
mRNA, which is translated very inefficiently in Xenopus 
oocytes. Exchange of the UTR segments between different genes 
showed that this inhibitory effect lies mainly in the 3' UTR, 
with only a minor effect of the 5'UTR (Kruys et al, 1987). 
Some other studies demonstrated that a correlation between 3 1 -
UTR sequences and stability of the mRNA (Caput et al, 1986; 
Jones and Cole, 1987). The significance of the unusually long 
3~UTR in the 4.0 an 5.0 kb cathepsin B mRNAs remains unknown. 
The possibility of their effects on the stability of the mRNAs 
or translation of the enzyme needs further investigation. 
High molecular weight forms of cathepsin B have been 
reported in rat islets (Docherty et al, 1983), rat insulinoma 
(Docherty et al, 1984) and different human and mouse tumors 
(Recklies et al, 1982a and 1982b; Mort et al, 1984, Dujeck et 
al, 1984). Present data have excluded the possibility that 
the large molecular forms of cathepsin B are from alternative 
splicing of cathepsin B mRNA or coding mutation of the gene. 
Considering the fact that these large molecular forms of 
cathepsin B can be cleaved in vitro by pepsin to generate a 
smaller, enzymatically active species (Docherty et al, 1983; 
Mort et al, 1983), these larger forms are most likely 
precursor forms of mature cathepsin B resulting from altered 
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intracellular post-translational processing. 
In any event, the differences in length of the three 3'-
untranslated regions, 806 bp, 2,417 bp, and 3,596 bp, 
respectively, are sufficient to account for the size 
differences observed between the 2.2 kb, 4.0 kb and 5.0 kb 
cathepsin B transcripts on Northern blots. RNA protection 
experiments using B16a tumor RNA and mouse kidney RNA indicate 
that the cathepsin B transcripts in both kidney and B16a 
melanoma have the same start sites. Thus, the cathepsin B 
gene promoter seems normal in the B16a tumor and the increased 
cathepsin B mRNA level is more likely due to increased mRNA 
stability, up-regulation of an enhancer element in the gene, 
or the unmasking of a cryptic enhancer. 
MOUSE CATHEPSIN B GENE STRUCTURE 
The mouse cathepsin B gene is comprised of 10 exons and 
9 introns that span about 20 kb of DNA. Unlike some other 
genes, such as insulin receptor (Seino et al, 1989), whose 
exons encode well defined functional units, mouse cathepsin 
B gene structure does not correspond well to the units of 
function. This characteristic was observed for rat cathepsin 
H (Ishidoh et al, 1989a), L (Ishidoh et al, 1989) and other 
cysteine proteinase genes such as aleurain, CPl, CP2 and CANP 
(Whitter et al, 1987; Pears et al, 1987; Emori et al, 1986) 
as well. An intron-exon junction is located immediately after 
the active site cysteine in the mouse cathepsin B gene. It 
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seems a common characteristics for cysteine proteinases that 
an intron-exon splicing site is always near the active site 
cysteine, within the highly conserved region (Ishidoh et al, 
1987a and 1987b; Whitter et al, 1987; Pears et al, 1987; and 
Emori et al, 1986). In Figure 32, the gene organizations of 
rat cathepsin B and mouse cathepsin B are compared with that 
of rat cathepsin H (Ishidoh et al, 1989a) and L (ishidoh et 
al, 1989b). Although I did not clone rat cathepsin B gene, 
it can be assumed that rat cathepsin B has the same gene 
organization as mouse cathepsin B because they have highly 
homologous sequences. It is clear that cathepsin B, cathepsin 
H and cathepsin L sequences have a relatively high degree of 
identity in their active site cysteine regions and carboxyl-
terminal regions. Eight identical amino acid sequences are 
found in the vicinity of active site cysteine in the three 
cathepsins. The exon-intron organizations of these genes are 
partially conserved in evolution, two intron-exon junctions 
are found in the same positions for cathepsin B and cathepsin 
H and for cathepsin H and L, respectively, while one intron-
exon junctions are found in the same positions for cathepsin 
B and L. The similarities suggest that they are from a common 
ancestral gene. While the difference between the genes could 
be interpreted in terms of models involved intron loss or 
insertion during evolution, studies in other systems suggest 
that intron loss is more likely (Gilbert et al, 1986). 
Comparison of cathepsin B, H and L genes with other cysteine 
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Figure 32. Alignment of the Amino Acids Encoded by Mouse 
Cathepsin B, Rat cathepsin B, L and H 
Single-letter amino acid code is used. Identical 
residues are boxed. Dashes indicate gaps introduced to 
generate this alignment. The positions at which introns 
interrupt the sequences are denoted by arrowheads. The arrows 
indicate the potential proteolytic cleavage sites. Circles 
indicate the active site cysteines and histidines. 
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Figure 32. Alignment of the Amino Acids Encoded by Mouse 
Cathepsin B, Rat Cathepsin B, L and H 
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proteinase genes such as aleurain, CPl, CP2 and papain (Michel 
et al, 1970; Husain and Lowe, 1970) shows that the gene 
sequences and organizations of cathepsin H, L are more closely 
related to those of the plant cysteine proteinases than that 
of cathepsin B, suggesting in the evolution process cathepsin 
B gene diverged earlier than cathepsin H and L from their 
common ancestral gene. 
In comparison of the GC contents of exons in mouse 
cathepsin B with that in rat cathepsin H and L (Table 10) 
indicates a similarity: all first exons of the three lysosomal 
cysteine proteinase genes have high GC contents (cathepsin B: 
73%, cathepsin H: 69%, cathepsin L: 61%) 
The 5'-upstream sequence of cathepsin B has something in 
common with that of cathepsin L: both sequences are GC rich, 
both have several potential Spl binding sites, and both lack 
TATA motif. Thus, both genes have the features of "house 
keeping " genes which are constitutively expressed for normal 
cellular functions. Other housekeeping genes which have been 
cloned include adenosine deaminase gene (Valerio et al, 1985), 
dihydrofolate reductase gene (Yang et al, 1984) and insulin 
receptor gene (Araki et la, 1987; Seino et al, 1989) et al. 
There are also some differences between the putative promoters 
of the cathepsin B and L genes. The putative promoter of the 
cathepsin B gene is far away (4.75 kb) from the second exon 
while that of cathepsin Lis very close (0.7 kb) to the second 
exon. The putative promoter of cathepsin B dose not have CAAT 
Table 10. Comparison of GC Contents of Exons in Mouse 
Cathepsin B, Rat Cathepsin H and Rat Cathepsin L 
135 
-----------------------------------------------------------
Exon 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
Cathepsin B 
(%) 
73 
59 
51 
53 
47 
48 
54 
45 
55 
46 
cathepsin H 
(%) 
69 
34 
49 
42 
51 
58 
55 
55 
46 
44 
44 
50 
Cathepsin L 
(%) 
61 
50 
51 
49 
48 
49 
43 
38 
The data for cathepsin H is from reference (Ishidoh et 
al, l989a) . The data for cathepsin L is from reference 
(Ishidoh et al, 1989b). 
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box and AP-2 binding sites while that of cathepsin L dose. 
It has been reported the tissue distributions of cathepsin B 
and cathepsin L were different in normal tissues (Kominamal 
et al, 1985; Banda et al, 1986; Qian et al, 1989) . In 
addition, differential increases in the expression and 
secretion of cathepsin B and cathepsin L are among in 
different tumor cell variants (Qian et al, 1989; Keppler et 
al, 1988b) and transformed fibroblasts (Troen et al, 1987; 
Gottesman and Sobel, 1980) . The differences in their putative 
promotor regions may account, in part, for the differential 
expression of these two cathepsin genes in normal and tumor 
tissues. 
Analysis of the cathepsin B gene and the cathepsin B mRNA 
from B16a melanoma reveals that three potential 
polyadenylation sites are present in exon 10 of the gene. 
This information suggests that the three cathepsin B mRNA 
transcripts are from the same gene and very likely result from 
alternative usage of polyadenylation sites. 
The cathepsin B gene information generated in this work 
will prove useful in the study of the mRNA transcription, 
translation, stability and regulation of gene expression of 
this enzyme in normal cells and in malignant cells. 
POSSIBLE MECHANISM FOR ELEVATED CATHEPSIN B mRNA IN B16a 
MELANOMA CELLS 
The mechanism of the selective elevation of cathepsin B 
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mRNA levels in the tumor cells can not be finally concluded 
in this study. However, a number of possible explanations 
can be eliminated. These are: amplification of cathepsin B 
gene in the melanoma cells, gross chromosome rearrangement 
leading to an altered gene expression, and mutation within the 
exons of the gene. The extended half-life of cathepsin B mRNA 
in the melanoma cells indicates that the stabilization of 
cathepsin B mRNA in the melanoma cells can account, at least 
in part, for the elevated cathepsin B mRNA levels in the tumor 
cells. It can not account, however, for the entire 
differences in mRNA levels among the three melanoma variants 
as the half life of cathepsin B mRNA in B16a (high metastatic 
potential) is only a slightly longer than that of Bl6Fl (low 
metastatic potential). 
Half-lives of turnover for eukaryotic mRNAs and proteins 
range from a few minutes for highly regulated gene products 
such as oncongenes and rate-limiting enzymes, to more than 100 
hours for very stable species. The average half-time of 
turnover for mRNA in eukaryotic cells is about 10-20 h. A 
mathematical model described by Hargrove et al (1989) shows 
that relative rates of mRNA transcription and translation and 
comparative stabilities of mRNAs and proteins contribute 
equally to the relative concentrations of different gene 
products in cells. Because transcription of many genes occurs 
at a significant basal rate in vertebrate tissues, a change 
in mRNA stability can be just as effective as a change in 
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transcription in changing the rate of protein synthesis. The 
utility of controlling mRNA stability owes partly to the very 
large amplification that occurs in protein synthesis; 
typically more than 104 mol of protein are synthesized per 
mole of mRNA (Palmiter, 1975). This result can be understand 
in terms of translational yield, which is defined as the 
number of molecules of a protein synthesized per molecule of 
specific mRNA per minute, multiplied by the mean life of the 
mRNA (mean life = half-life divided by 0.693) (Hargove and 
Schmidt, 1989) . Thus, it is energetically favorable to 
increase protein synthesis by making better use of existing 
mRNA or to decrease protein synthesis by degrading the 
relatively small amount of mRNA in the transcribed pool. 
Clearly, the increased cathepsin B mRNA stability in B16a 
melanoma cells could result in the increased protein synthesis 
and contribute to the increased cathepsin B activity found in 
the tumor. 
The unusually long 3'UTR sequences in the larger 
cathepsin B transcripts in the B16 melanomas appear to 
contribute to the increased stability of the mRNAs as we can 
see that the 4.0 kb transcript is very stable in the Northern 
blot analysis (Fig. 30). However, this may not be the only 
cause since the 2.0 kb transcript in the melanoma cells is 
also quite stable as shown in Fig. 30. Other possibilities 
include the presence of a factor or factors in the melanoma 
cells, which is responsible for the stabilizing the cathepsin 
B mRNA in the melanoma cells. 
investigated further. 
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This hypothesis need to be 
Although preliminary evidence has shown cathepsin B mRNA 
expression in the B16 melanoma cells is regulated, at least 
in part, at the posttransciptional level, it is possible that 
transcriptional regulation also occurs. The evidence for this 
is that the large differences in cathepsin B mRNA levels 
between the B16a melanoma variants despite similar half lives 
for their cathepsin B mRNAs. With the mouse cathepsin gene 
and its 5'-upstream region now available, it should be 
possible to determine how transcription of the cathepsin B 
gene is regulated in the tumor cells and in normal cells. 
CHAPTER VI 
CONCLUSIONS 
I. The relative mRNAs of five lysosomal cathepsins {B, 
D, H, L and S) have been measured in rat and mouse tissues 
including kidney, lung, liver, spleen, thymus, uterus, testes, 
skin, brain and pancreas. The differential distribution of 
these cathepsins in the tissues suggest each cathepsin has its 
specific functions and may be individually regulated. 
II. Cathepsin B mRNA level is specifically elevated in 
rat Walker-carcinosarcoma and mouse 816 melanomas. In 
contrast, cathepsin H, D, L and S mRNA levels are not elevated 
in the same tumors. The elevated cathepsin B mRNA level is 
in agreement with the increased enzyme activity in the 
melanoma cells and correlated well with the metastatic 
potential of the Bl6 melanoma variants. 
III. The selectively elevated cathepsin B mRNA is 
derived from tumor cells and not from contaminating 
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reticuloendothelial cells, such as macrophages. 
IV. The B16 melanomas express cathepsin B mRNA 
transcripts with the sizes of 2.2, 4.0 and 5.0 kb. The two 
larger transcripts were not detected in normal murine tissues. 
The cloned cDNAs from a Bl6a melanoma library indicate all 
three mRNA transcripts encode for the same protein sequence, 
which is also the same as preprocathepsin B from normal murine 
tissue. The two larger transcripts have unusually long 3 1 -
untranslated sequences which may result from modified 
termination of transcription of cathepsin B in the melanomas. 
v. Mouse cathepsin B gene consists of 10 exons spanning 
about 20 kb. The first exon and the putative promoter region 
are very GC rich and five Spl binding sites are present in the 
5'-flanking region which, however, has no TATA box. These 
characteristics suggest cathepsin B gene is a "housekeeping" 
gene and may be regulated, at least in part, by Spl 
transcriptional factors. 
VI. No gene amplification or gross chromosomal 
rearrangements were found for cathepsin B gene in the melanoma 
cells. Neither were there any mutations within the coding 
region of the gene. 
VII. cathepsin B mRNAs appear to have longer half-lives 
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in the mouse melanoma cells than mouse fibroblasts. The 
increased stability of cathepsin B mRNA in Bl6 melanoma cells 
may account in part for its increased level in the mouse 
melanomas. 
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